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PREFACE 
This thesis has begun to be tested the traits associated with Proprotein convertase 
subtilisin/kexin type 9 (PCSK9) in mice model. During the past decade, studies on mice 
models and clinical trials have been convincingly established the role of PCSK9 with 
cholesterol homeostasis, however PCSK9 role in peripheral atherosclerosis development is 
still under investigation, and there is a contradictory results on glucose homeostasis too. 
Results from our previous study has demonstrated that vascular smooth muscle cells 
expresses PCSK9, and also marked its presence in the atherosclerotic plaque. This led us to 
study the role of locally produced PCSK9 protein on vascular remodelling especially in 
atherosclerotic plaque composition. 
For this purpose, the mice with or without PCSK9 gene were generated of C57/BL6 
background. At prima facie, we first studied the role of PCSK9 in peripheral atherosclerosis 
progression and glucose homeostasis. Secondly, we also intended to observe the replica of 
results from mice in humans. For this purpose, we chose to study the effect of PCSK9 loss 
of functioned variants especially R46L (rs11591147), which is more commonly found in 
Caucasian population, and was previously studied in a large cohort of Dallas heart study 
(DHS). Together with the screening of PCSK9 R46L gene variants, we also choose to 
determine the levels of plasma PCSK9 in our studied cohort. This helped us to understand 
the effect size of gene variants not only on the lipid phenotypes but also on the plasma 
PCSK9 levels and plasma PCSK9 levels mediated effects on metabolism. Together with the 
study of PCSK9, we also selected few of the recently identified polymorphism on LDL-R 
modulating genes discovered in a GWAS based or mono-genic studies, these genes include 
Inducible degrader of LDL-R (IDOL) and G-protein coupled estrogen receptor (GPER) 
Rationality of choosing genetic variants study for PCSK9, IDOL and GPER gene.     
The major risk associated with cardiovascular diseases (CVDs) are high blood pressure, high 
cholesterol level, cigarette smoking, diabetes, obesity, physical inactivity, and unhealthy 
diets. CVDs may also result from a variety of genetic causes, including single nucleotide 
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polymorphism (SNPs), heterogenetic changes and other environmental factors. 
Urbanisation, pollutions, Economic transition, industrialization and western life style also 
promotes heart diseases. Heart diseases have no social, geographical, gender or ethnic 
boundaries, and it makes it important cause of worldwide mortality. It has been reported 
from various studies, where CVDs was found a major health burden and causal risk of 
highest mortality and morbidity worldwide[1][2][3][4]. Of the estimated 16.6% million 
deaths attributed to CVD worldwide, 80% deaths were reported from developing countries. 
In recent years, several awareness programmes and high prognostic techniques/methods 
have immense impact on reducing CVD risk and further extended our understanding to 
unmask the complexity of CVD occurrence. With the advancement of various techniques to 
identify the causal root of CVD occurrence has greatly contributed in understanding the CVD 
complexity. Especially, recent evidences from Genome-wide association studies (GWAS) 
and mono-genic population based studies have immensely changed a prospective of risk 
related to CVDs, many gene to gene interaction and their relation to complex traits are a 
fascinating thirst area. Recent approaches of GWAS have been identified and characterised 
several unbiased evidences of the genes contributing to common cardiovascular disease 
traits, and a powerful tool to identify conditions influences by many genes and 
environmental factors at once. Maximum data from GWAS has been contributed to the 
depth of European genetic architecture. A complex genetic architecture and interaction 
with several endogenous and exogenous factors involving in risk is the primary challenge to 
solve the depth of network. 
Indeed, some recently identified single nucleotide polymorphisms (SNPs) in GWAS 
and other independent studies and evaluation of their contribution in lipid biology has 
shifted the paradigm in last decade. Few polymorphisms of lipid related genes have been 
identified as a potential marker to assess the future CVD risk, therefore, we chose to screen 
few of them to understand their potential role in Italian general population- enrolled in PLIC 
study (progression of lesion in intima-media of carotid artery), these genes includes 
Proprotein convertase subtilisin/kexin type 9 (PCSK9), Inducible degrader of LDL-R (IDOL) 
and G-protein coupled estrogen receptor (GPER). 
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With the surge to identify the penetration of the polymorphisms in these selected 
genes in our Italian cohort and their potential role in lipid phenotypes and risk of CVDs, We 
chose to identify the penetration and effect size of PCSK9- R46L(rs11591147), IDOL-N342S 
(rs9370867) and GPER-P16L(rs11544331) polymorphisms in Italian cohort.  
PCSK9 R46L has been identified in Whites subjects in a Dallas-Heart studies (DHS) 
with the penetration of about 3.2% and had a deep role in reducing the high cholesterol risk 
(-15%) and CVD risk (-47%) [5] and was later found associated with reduction in plasma 
PCSK9 levels too (-22.30%) [6]. On the other hand, the GWAS identified SNP- rs9370867 
(p.N342S; Asn- Ser substitution) on the IDOL gene had impact on lipid phenotypes in 
European descends, and was found with the frequency of about 49%-60% while it was only 
about 2%-8% in African (YRI), Asian (CHB and CHD) and Amerindians (Mayans) 
ancestries[7][8]. However, the studies of rs9370867 SNP on IDOL gene studied in two 
different population and their association with lipid phenotypes- emerged with a mixed 
results, where MAF (25%) of risk allele (Asn) in Mexican dyslipidemic cohort had profound 
effect on cholesterol levels[9], and on the other hand, MAF (35%) of risk allele (Asn) in 
Brazilian cohort had no significant association with lipid phenotypes[10]. This variable 
association of gene polymorphism with specific trait is complex and require more attention, 
and might be utmost essential in therapeutic implications.  
We also chose to study GPER-rs11544331 (p.P16L) polymorphism which was 
suggested to be linked with high blood pressure and elevated total cholesterol levels in 
women, probably via elevated PCSK9 expression-shown via series of experiment on HepG2 
cell lines.  This sex-specific regulation of GPER dragged our attention too for its evaluation 
in Italian cohort.  
The reason of choosing these variants of three different genes (PCSK9, IDOL and 
GPER) was their direct link on lipid phenotypes via LDL-R modulation as reported by GWAS 
or Individual population based studies. With the immense literature search, we have not 
found any information about these SNPs studies (except PCSK9-R46L) on lipid phenotype in 
Italian population.  
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Therefore, we for the first time evaluated the penetration and effect size of IDOL-
N342S and GPER- P16L variants but also PCSK9-R46L on molecular phenotypes of lipid and 
peripheral atherosclerosis progression. In addition to the SNP screening, we also performed 
functional studies of our studied genes by invivo and invitro methods.  We use transgenic 
Mice model to understand the role of PCSK9 in carotid atherosclerosis progression and 
glucose metabolism. While functional characterisation of IDOL SNP was also evaluated in 
invitro analysis by selecting 5-5 subjects of each respective genotypes of the gene and 
quantified their scale of LDL uptake and LDL-R expressions and other lipid related gene 
expression. 
With this thesis, we will try to understand the role of PCSK9, IDOL and GPER gene on 
lipid homeostasis, glucose metabolism and peripheral atherosclerosis progression. 
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CHAPTER 1.  INTRODUCTION 
 
 
Section [A] LDL-receptor structure and physiologic function 
Section [B] Post-transcriptional modulators of LDL-R (extracellular and intracellular 
modulators) 
 [B1] PCSK9 (Proprotein convertase subtilisin/kexin type 9) role in LDL-R 
modulation 
 [B2] GPER (G-protein coupled estrogen receptor) role in cardiovascular 
system 
 [B3] IDOL (Inducible degrader of LDL-R) role in LDL-R modulation  
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SECTION A. LDL-R STRUCTURE AND PHYSIOLOGICAL FUNCTION 
1.1. Introduction and historical perspective 
The low-density lipoprotein receptor (LDL-R) is a cell surface glycoprotein and 
expresses ubiquitously, the major function of LDL-R is to pick up low-density lipoproteins 
(LDL) circulating in the bloodstream and transport them into the cells, thus play a critical 
role in the homeostatic control of blood cholesterol[11]. Brown and Goldstein originally 
hypothesised the role of membrane receptor in 1973 during their search for the molecular 
basis of Familial hypercholesterolemia (FH)[11][12][13][14], FH is inherited as an autosomal 
dominant trait and characterised as the exceptional increase in cholesterol levels in blood 
than normal levels. These high in cholesterol levels of FH patients causes severe clinical 
phenotypes and eventually one of the major factor causing heart attacks in their early life, 
therefore cholesterol synthesis was shown as a hallmark of FH,. During late 1960s or early 
1970s, Brown and Goldstein hypothesised that FH might not be due to the enzyme 
deficiency (as was earlier concept of FH), rather due to the defect in metabolic regulation 
or a defect in protein that participate in cholesterol regulation. 
The striking observation came from the classical experiment, where Brown and 
Goldstein first observed that how fibroblast cells stop endogenous production of cholesterol 
synthesis (by measuring HMG CoA reductase activity) when exogenous cholesterol supplied 
via LDL in the serum, while it was not true when fibroblast from FH patients cultured and 
supplied with exogenous LDL- they suspected that fibroblast have some feedback 
mechanism of endogenous cholesterol synthesis and addition of LDL in culture depleting 
the HMG-CoA activity. They further demonstrated that the normal fibroblasts had high-
affinity binding sites for LDL particles on their surfaces, while the fibroblast from FH patients 
had impaired affinity for LDL binding on their surfaces [15]. However, not all lipoproteins 
could suppress the HMG-CoA activity. A decade later, the gene encoding the LDL-uptake 
receptor was cloned and sequenced[16][17][18]. Shortly after the discovery of LDL-R as a 
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membrane receptor responsible to internalise circulating LDL, Brown and Goldstein found 
that LDL-R itself undergoes to feedback regulation, LDL-R expression is largely relies on 
intracellular cholesterol trafficking, where increased intracellular cholesterol levels 
decreases the production of LDL- receptor[19], this was in parallel to the HMG-CoA 
reductase reduced activity. The underlying mechanism behind this feedback mechanism 
remained unclear uptil next two decades when Brown and Goldstein further discovered a 
pair of sterol-regulated, membrane bound transcription factors called SREBPs[20][21]. 
1.2. Physiologic ligands, endocytosis and receptor recycling pathway 
The most virtual physiologic ligand for the LDL-R is LDL, which carries a single copy 
of apolipoprotein B-100 (ApoB100). In later studies, LDL-R were also identified as a binding 
mediator for ApoE containing lipoprotein particle. LDL-R binding to LDL take place in 
extracellular environment, this complex (LDL-R-LDL) further enters the cell by endocytosis 
via clathrin-coated pits and then delivered to endosomes[22][23]. The acidic environment 
of endosome allows the dissociation of the complex[24], and LDL-R are subsequently 
returned to the cell surface in a process called “receptor recycling”- [Figure 1]. The ligand 
binding to LDL-R requires Ca²⁺. 
 
Figure 1. Sequential steps in the LDL receptor pathway of mammalian cells. 
A schematic representation of LDLR mediated LDL clearance from circulation. [Figure adapted from 
Goldstein. J et al; ATVB. 2009 Apr; 29(4): 431-438]. 
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1.3. Structural organisation of LDL-R 
The cytogenetic location of human LDL-R is at small arm of chromosome 19 
(19p13.2) and contains 18 exons. This human 45kb gene encodes 839 amino acids protein, 
which carries three types of extracellular modules in its structure[16][17]. The LDL-R is 
synthesised as a 120-kD glycoprotein precursor that undergoes structural change to a 160-
kD mature glycoprotein through the covalent addition of a 40-kD protein[25]. 
The N-terminal ligand binding domain (LBD) encoded by exons 2 to 6 and consists of 
7-contiguous cysteine-rich, complement-type repeats and named LDL receptor type A 
repeat (LR), each LR module is about 40-residues in length, has six conserved cysteine 
residues, and contains a conserved acidic region near C-terminus which serves as a calcium-
binding site[17]. Adjacent to LBD domain, it also contain three EGF precursor homology 
domains (comprised of 400 amino acids encoded by exons 7 to 14), this domain of LDL-R is 
responsible for the dissociation from the lipoproteins in the endocytosis machinery. The 
another domain in LDL-R is called as O-linked glycosylated domain [17], encoded by exon 15 
and comprised with 58 amino acid sequence that is enriched in serine and threonine amino 
acids, this domain of LDL-R is serve to bind with O-linked sugar chains. A domain which 
provide support to LDL-R flanking as transmembrane is “membrane-anchoring domain” 
encoded by exon 16 and 5’ end of exon 17, this domain is essential to the attachment of the 
receptor to the cell membrane [Figure 2]. The last domain is “cytoplasmic domain or a 
cytoplasmic tail consists of 50 amino acids encoded by remainder of exon 17 and 18, The 
cytoplasmic tail contains an NPxY sequence that directs the receptors to clathrin coated 
pits[26][27], this region is also required for proper sorting of LDL-R [28][29].  
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Figure 2. Biological structure of transmembrane LDL-receptor (LDL-R) 
Figure depict the domain organisation of the LDLR. “LA” domain- LDL receptor type A also called LBD 
(Ligand binding domain); “LY”- repeats containing a YWTD consensus motif; “EGF” domain-Epidermal growth 
factor precursor homology region. [Figure adapted from Jeon H. Blacklow S et al. Annu. Rev. Bichem 2005. 
74:535-62]. 
 
 
1.4. Genetic, physiologic modification in LDL-R and role in Familial 
hypercholesterolemia 
Nearly all relevant studies have demonstrated that the major function of LDL-R is to 
control plasma cholesterol levels, and mutations in the LDL-R gene causes familial 
hypercholesterolemia (FH)- an autosomal dominantly inherited disease, which is the most 
common monogenic gene defect in LDL-R found in almost 1:500 people in a heterozygous 
forms (LDL levels = between 5mmol/L upto 12 mmol/L),. While the homozygote mutation 
in LDL-R expresses non-functional protein and found with a frequency of about 1:10,000, 
with a dramatic increases in blood cholesterol levels (LDL levels = >12 mmol/L), which in 
turns represent severe clinical phenotypes including cutaneous xanthomas and 
atherosclerotic plaques at a very early age leads to premature death- [Figure 3]. The 
heterozygotes patients carries about half of the normal levels of LDL-R, but still prone to 
develop xanthomas and atherosclerotic plaques, due to reduced capability of cholesterol 
clearance. LDL-R mutations, generally classified into five classes viz “ Defect in LDL-R 
synthesis”, disturbance in transportation to the cell surfaces”, “Binding to ligands”, 
“clustering of the receptor in the endocytic vesicles” and recycling route defect”[11][14]. To 
date, more than 1400 point mutations and small deletions or insertions associated with FH 
have been reported in the LDL-R gene. 
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Figure 3. Clinical manifestation of Familial hypercholesterolemia (FH):-  
This figure depict the deposition of cholesterol in patients with FH:- Top left panel: a white lining of  
cholesterol deposition called “arcus conealis” especially seen on the lower part of cornea. Top right  
panel:- Xanthomas on “ Achilles tendons” above the heels. Bottom left panel:- Xanthoma formation   
in the tendons of the middle and ring fingers. Bottom right panel:- skin xanthomata on the hands of  
a child with homozygous FH 
 
SECTION B: POST-TRANSCRIPTIONAL MODULATORS OF LDL-R (EXTRACELLULAR AND INTRACELLULAR 
MODULATORS) 
Due to the mounting knowledge of molecular interaction of LDL-R with other 
proteins [Figure 4] and their role on LDL-R modification elaborated the functional aspect of 
these proteins in lipid biology. LDL-R major function is to regulate circulating LDL levels, 
however, LDL-R functionality and its levels also gets regulated by other proteins, these 
proteins interacts via both extracellular domains or intracellular domains of LDL-R, thereby 
regulate LDL-R functionality at post-transcriptional level. The two most studied post-
transcriptional modulators of LDL-Rs are Proprotein convertase subtilisin/kexin type 9 
(PCSK9) and Inducible degrader of LDL-R (IDOL)[30][31]. In this thesis, we will further 
describe the underlying mechanism of these post-transcriptional modulators in LDL-R 
viability/functionality.  
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Figure 4. Protein network those interact with LDL-R 
Proteins those interact with LDLR in physiological condition. Most of the depicted proteins have been 
studied extensively, and two proteins on the right hand side (PCSK9 and IDOL-also called MYLIP) was also 
choosen in our study. 
 
 [B1] PCSK9 ROLE IN LDL-R MODULATION  
1.5.  General Introduction and historical perspective 
The first proprotein protease discovered was that of kexin-protease (KEX2 gene) 
from yeast [S.cerevisiae], soon characterised as  a Ca²⁺ dependent serine protease[32][33], 
later homologues proteases in humans were also discovered[34][35]. The mammalian 
proprotein convertases (PCs) family includes 9 members to date, and well characterised 
since their respective discoveries, the first seven enzymes (Furin, PC1/3, PC2, PC4, PACE4, 
PC5/6 and PC7) of PCs families cleaves pro-proteins (precursor proteins) at multi-basic 
(K/R)-(X)n-(K/R) !  motif, where; X-represent any amino acid besides cysteine, and n= 0,2,4, 
or 6 [Figure 5]. The eighth member is the pyrolysin-like subtilisin kexin isoenzyme-1 (SKI-
1)[36], and also known as site-1 protease (S1P)[37] and cleaves substrate at the non-basic 
motif (R/K)X-(hydrophobic)-X!, where X is variable. The ninth member of PCs widely known 
as PCSK9 which cleaves the sequence VFAQ152! Within its pro-segment [38][30]. 
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A 22kb human Proprotein convertase subtilisin-kexin type 9 (PCSK9) gene located in 
a region which is linked to ADH in a small arm of chromosome 1p32, and contains 12 exons 
and 11 introns. The gene encodes a 692-amino acid (aa) protein, which is a 9th member of 
proprotein convertase family belongs to serine proteases and known to deteriorate the LDL-
R activity in liver, eventually causes hypercholesterolemia and hence a suitable target for 
therapeutic intervention. PCSK9 gene architecture plays a pivotal role and decides the fate 
of LDL-R viability, GOF mutations in PCSK9 gene causes severe hypercholesterolemia and 
coronary heart disease (CHD), conversely, LOFs mutations have opposite effect. 
 
Figure 5. Structure of human Proprotein convertases. 
Schematic representation of the human proprotein convertases. Each PC-contains a N-terminal signal  
domain, Prodomain, Catalytic domain and P-domain responsible for calcium binding and pH  
dependence. The PCs contain either serine and threonine rich region or cysteine rich regions, and  
sometime contains transmembrane domain followed by C-terminal cytoplasmic domains. [Figure  
adapted from Seidah.N et al, Nat. Rev drug discovery. 2012 May; 11, 367-383] 
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1.6. Benchmark of PCSK9- From discovery to therapeutic application 
PCSK9 high expression was initially reported during apoptosis in neuronal cells[30], 
also called as NARC1 (neural apoptosis regulated convertase-1), it was in 2003, when the 
first link of PCSK9 in cholesterol metabolism was discovered[39], which opened a new 
insight into the cardiovascular biology. PCSK9 role in cholesterol metabolism rapidly took 
into pace when two causative new mutations (S127R and F216R) in two French autosomal 
dominant hypercholesterolemia (ADH) families were detected between D1S197 and 
D1S2890 markers in chromosome 1p34.1-p32 (OMIM 63776), that harbouring 41 genes 
including PCSK9. Later, structural and functional studies revealed that the severe clinical 
output of these functional variants was due to their enhanced binding activity and 
degradation capability to LDL-R[40][41]. Although, a pre-mapped region about 17cM 
between markers D1S2130 and D1S1596 in chromosome 1p32 was already found linked to 
ADH in Utah population [42] in early 2000s, but remained unidentified for the gene uptil 
2004, the region was later found overlapped with previously identified locus causing severe 
hypercholesterolemia in French and Spanish families[43]. All these discoveries established 
the role of PCSK9 gene in hypercholesterolemia [Figure 6]. Conversely, discovery of two loss-
of-functioned (LOFs) mutations in African-Americans (Y142X and C679X) revolutionised the 
era into therapeutic possibility[44], these mutation had about 40% and 88% reduction in 
cholesterol and CHD risk respectively. Apart from the PCSK9 genetics, several endogenous 
and exogenous factors also modulates PCSK9 expressions, including age, gender, dietary 
habits, life style, drugs etc, in short, Statins are the cornerstone of lipid-lowering treatment, 
but prevalence of persistent lipid abnormalities was often seen in many patients under 
Statin treatment, and often remained a challenge for the clinicians. Biochemical studies 
later discovered the expression of PCSK9 gene goes upregulated upon statin treatment via 
sterol regulatory element binding protein (SREBP2) pathway. This eventually reducing the 
efficacy of statins[45][46]. Thus PCSK9 protein was hotcake for pharmaceutical intervention, 
and various therapeutic alternatives were proposed and tested, including- Monoclonal 
antibodies, peptides mimics, vaccinations, anti-sense oligonucleotides etc. A meta-analysis 
of 24 clinical trials of PCSK9 monoclonal antibodies has shown the improved cholesterol 
profile, cardiac health and all-cause mortality[47]. PCSK9 Monoclonal antibodies 
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Evolocumab (Amgen), Bococizumad(Pfizer) and alirocumab(Aventis/Regeneron), has been 
approved. 
 
Figure 6. Mapping of common natural mutants of PCSK9. 
A cartoon on left panel depicted the mutation carrying on different domains of PCSK9 while table on 
the right side depict the phenotype caused by respective mutant. [Figure adapted from Hampton E. 
et al; PNAS 2007 Sep 11;104 (37): 14604-9]. 
 
1.7. Structural and functional activity of PCSK9 
PCSK9 is initially synthesized as a zymogen (~74kDa proprotein), from which 
proteolytic cleavage of the ~14kDa N-terminal prodomain results in ~60kDa mature form 
consist of Prodomain as a chaperon, catalytic domain and CHRD domain[48][49][50][51]. 
The inactive form of PCSK9 also make its volume in plasma at certain extent. The furin 
mediated cleavage at Arg218! in PCSK9 generates ~55kDa protein. The liver is the major site 
of PCSK9 secretion[30] [52], other site also contribute in plasma PCSK9 volume includes 
kidneys, small intestine and brain [52][53][54][55][56]. Hepatocytes secreted PCSK9 
contributes about 2/3 volume of blood cholesterol [52], due to its exacerbate ability to 
downregulate LDL-R, PCSK9 binding  and internalisation to surface LDL-R thought  to be 
rapid and major pathway of PCSK9 clearance, with 5-minute half-life of the recombinant 
human protein injected into mice, [55][56], and prolonged stay circulation in LDL-R deficient 
mice[55]- [Figure 7]. 
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PCSK9 shares a structure homology with other proprotein convertases (PCs) and 
contains four major domain within, namely- signal peptide (1-30 aa), Prodomain (31-152 
aa), Catalytic domain (153-425 aa) and c-terminal or Cys-his rich domain (CHRD) (426-692 
aa). However, unlike other PCs, PCSK9 undergoes single autocatalytic intramolecular 
cleavage at non-basic amino-acid residue Gln152Ser at its prodomain[48][49], this cleavage 
helps PCSK9 in secretion to extracellular environment, however, prodomain remained 
bounded as chaperon and mask its future proteolytic activity, the chaperon bounded PCSK9 
displayed it binding ability to LDL-R and further implicated to the cholesterol homeostasis. 
The main function of PCSK9 is to bind with transmembrane LDL-R and mediates its 
degradation [Figure 7]. However, PCSK9 in circulation remained in both mature (Cleaved 
~62kDa) and inactivated form (~55kDa), ex-vivo data revealed that furin ability to cleave 
PCSK9 at Arg(218!)-Gln(219!) reduces plasma PCSK9 levels by ~50% and remained of ~55kDa 
in size.[57], while 35% increases in PCSK9 mRNA and 26% drop in LDL-R protein levels in 
mice lacking furin gene was observed. Mass spectrometry analysis revealed that in vivo 
cleavage of PCSK9 at Arg218! Resulting in pyroglutamic acid formation of the nascent N-
terminus amino acid corresponding to Gln!219 of secretory PCSK9.  
 
 
Figure 7. Molecular mechanism of PCSK9 mediated LDLR degradation  
  
A complex of PCSK9-LDL-LDLR formed extracellularly and internalised via clathrin coated pits, 
fuses into endosome and subsequently undergoes lysosomal degradation. [Figure adapted from 
Lambert et al, JLR. 2012. 53:2515-2524]. 
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The first evidence of PCSK9 activity in reducing hepatic LDL-R protein emerged from 
the mice models, and led the discovery of the molecular mechanism of PCSK9. Briefly, the 
PCSK9-LDL-R complex [Catalytic domain of PCSK9- EGF-a domain of LDL-R] initiates at 
extracellular surface and subsequently internalises via clathrin coated pathway with the 
help of ARH-adaptor protein activity. The complex further fuses into endosome, where 
secondary folding of PCSK9 to LDL-R requires to sustain in the late acidic endosome, CHRD 
domain of PCSK9 and LBD-domain of LDL-R binding prevent the escape of PCSK9-LDL-R 
complex from acidic endosomic environment [Figure 8]. This complex eventually routed for 
lysosomal degradation, however, with unknown mechanism. 
Intracellular binding of PCSK9 to LDL-R is also studied, it is evident from few studies 
that PCSK9 mediates LDL-R degradation in ARH-knockout mice too, suggesting that PCSK9 
also promotes intracellular degradation of LDL-R before reaching into basolateral surface of 
the hepatocytes. 
 
 
Figure 8.  Ribbon diagram of PCSK9-LDLR complex.  
The prodomain and catalytic domain of human PCSK9 are shown in purple and light brown color,  
respectively; the extracellular domain of LDL-R is shown in light green.[Figure adapted from Surdo Lo  
et al; EMBO Rep. 2011 Dec 1;12(12): 1300-5]. 
PCSK9 also downregulates LDL-R family members like VLDLR, LRP1, ApoER2. 
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1.8. Genetic architecture of PCSK9 and role in cholesterol homeostasis. 
Genetic mapping of small arm of chromosome-1 identified a 22kb PCSK9 gene which 
contains 12 exons and 11 introns, this gene encodes a protein comprised of 692aa -which 
belongs to proprotein convertase family. The PCSK9 gene is located in the locus which was 
found linked with ADH in French families. The first two gain of function discovered on PCSK9 
was S127R and F216L from French ADH families, which led PCSK9 as the 3rd gene causing 
autosomal dominant hypercholesterolemia (ADH). Gain of function (GOF) mutations on 
PCSK9 gene causes severe cholesterolemic phenotypes and a risk of CVD. The another most 
potent mutation was D374Y, which has been shown to increase the interaction between 
PCSK9 and LDL-R by 5-30 folds, firstly found on Utah and Norwegian population. D374 is a 
surface amino acid and makes no contacts with other amino acids in the PCSK9 structure. 
Structure analysis revealed that D374Y mutation causes an increase in affinity for the LDL-R 
by allowing a hydrogen bond or pi stacking interaction to form between PCSK9 and H306 of 
the LDL-R-EGF domain. Few gain-of-function (GOFs) and loss-of-function (LOFs) depicted in 
[Figure 9] 
 
Figure 9.The structure of proprotein convertase subtilisin kexin type 9 (PCSK9) 
Structure of PCSK9 contains 3 major domain (Pro, Catalytic and CHRD or C-terminus) after  
detaching from signal peptide or signal sequence (SS). Several gain-of-function (GOFs) and loss-of- 
functions (LOFs) identified in PCSK9 protein causing hyper and hypocholesterolaemia respectively.   
[Figure adapted from Horton.J et al- Trends in biochemical sciences 2007 Feb 32(2): 71-7]. 
Introduction 
18 
 
Several other single nucleotide polymorphisms has been detected and characterised 
on PCSK9 gene. Two Loss of function (LOF) mutations Y142X and C679X results in truncated 
versions of PCSK9 that disrupt proper folding and secretion while L82X (another LOF) 
prematurely terminate protein translation within the prodomain. Mutation at 253 aa 
position (L253F) on catalytic domain results in defect in autoprocessing of the protein. R46L 
is the most studied LOF variant in Caucasian subjects, also impaired hepatic secretion of 
PCSK9 and reduces the protein volume in plasma. Several additional PCSK9 variants are 
associated with reduced plasma LDL levels and reduced cardiovascular risk but their mode 
of action has not been elucidated yet. 
 
1.9. Population, gender and age disparity in PCSK9 expression. 
Inter-individual genetic makeup, age, gender and population are the major factors 
influencing PCSK9 levels and its functionality. Fluctuation on plasma PCSK9 levels has been 
advised in many studies, low in early age and increasing in concentration in later ages 
especially in women.  In general, women plasma carries more load of PCSK9 protein than 
their age-matched men, and this goes further highest in post-menopausal state. Data from 
recent study encompasses the instability of plasma PCSK9 levels exist right from the birth, 
a difference of 2 fold was there when analysed the fetus serum for PCSK9 levels than mother 
[58]. Further age and sex biasness also emerged from cross-sectional studies on 1739 youth, 
where plasma PCSK9 levels were higher in 9 years of boys group than their age matched 
girls (+10.78% at 5th percentile and +6.94% at 95th percentile), while girls of 13 years 
(+13.12% at 5th percentile and +8.28% at 95th percentile), and 16 years (+37.68% at 5th 
percentile and +40.97% at 95th percentile) age groups had increased concentrations of 
plasma PCSK9 protein than boys of similar age group, which indicates the strong 
intervention of hormonal regulation[59]. 
Plasma PCSK9 levels has been found varies among population to population too, and 
stressing for additional dependency factors like ethnicity and demography[6][60]. 
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1.10. Transcriptional, hormonal and dietary regulation of PCSK9 expression 
PCSK9 gene carries the functional sterol regulatory element (SRE) at its proximal 
region and is the most conserved transcriptional motif targeted by SRE-binding proteins 
(SREBPs)- A master transcriptional factors in cholesterol regulatory pathway. SREBP2 
majorly plays a key role in regulating or co-regulating PCSK9 and LDL-R receptor expressions 
to maintain intracellular sterol levels. 
The unbiased SREBPs dependent mechanism was described shortly after  the 
discovery of PCSK9 in 2003, where mice liver had less PCSK9 mRNA when mice were stressed 
on cholesterol rich diet, while had higher PCSK9 mRNA in SREBP1a and SREBP2 
overexpressing mice [61]. In addition certain lipid lowering drugs especially Statins also had 
impact on PCSK9 expression via SREBP2 pathway[62]. SREBP-1c was also implicated in 
postprandial insulin upregulation of PCSK9 gene expression in hepatocytes [63]. Similarly, 
activation of HNF1α also exert in PCSK9 transcription, which binds to an element located 28 
nucleotides (nts) upstream of the PCSK9-SRE region, this site is conserved and not present 
in LDL-R promoter, hence unlike SREBPs, HNF1α only target PCSK9 and not LDL-R [64]. 
Certain other repressor of PCSK9 transcription were recently identified. Berberine 
and Curcumin suppresses HNF1 α activation hence negatively affect in PCSK9 transcription 
too, similarly insulin also exert dual effect on PCSK9 expression, where insulin mediated IRS1 
activation leads the activation of mammalian target of rapamycin complex 1 (mTORC1) 
resulting in profound  reduction of HNF1 α and eventually less PCSK9 transcription [65]. 
PCSK9 expression were also found higher in a gender specific manner, women generally 
carries higher PCSK9 levels than age-matched men, and this goes further goes higher in their 
post-menopausal state. Hormonal intervention were long been suspected for the cause, 
recent evidences also support the role of Estrogen in controlling PCSK9 expression, however 
the true mechanism is still need to evaluate. 
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1.11.   PCSK9 role in extrahepatic tissues (adipose tissue, small intestine, 
pancreatic β-cells, kidney). 
PCSK9 role in adipose tissue:- 
However, adipocytes do not expresses PCSK9, but it appears from recent findings 
that circulating PCSK9 can modulates the adipocytes functionality, and this physiological 
modulation is mediated due to its ability to downregulate VLDL-R. Results from both 
mice[66] and human models[67] exhibited that PCSK9 binding with VLDL-R initiate with the 
similar fashion as with LDL-R and eventually leads its downregulation. Mice lacking PCSK9 
genes (pcsk9 -/-) shows intact surface VLDL-R expression and enhanced uptake of 
triglycerides resulting in adipocyte hypertrophy[66]. It would be further interesting to see 
the effect of some LOF variants of PCSK9 role in fat metabolism. Human PCSK9 p.R46L is a 
strong loss of function variant and decreases about 53% plasma PCSK9 levels, however 
might be a strong indicator of further risk of central obesity, requires further attention. 
 
Role in Small intestine 
All vertebrates except some species of bovine expresses PCSK9 protein in various 
tissues including small intestine. PCSK9 expression in human, rodents and mice small 
intestine was also observed especially in the ileum region[52], and suspected for its localized 
physiological changes in addition to its secretory circulatory effects. Recent in vitro studies 
on human Intestinal epithelial cell line (parental Caco2 or cloned Caco 2/15) indicated PCSK9 
role in intestinal lipid metabolism[68][69][70]. PCSK9-WT and p.D374Y treated Intestinal 
epithelial cell line had profound increase in apical cholesterol transporter proteins (NPC1L1, 
CD36 and SRB-1) and exhibited diminished LDL-R activity at the basolateral membrane of 
intestinal epithelial cells while restoration was observed in PCSK9 deficient cells [69]. 
Exogenous treatment of PCSK9 were also related with decreased activity of HMG-CoA 
reductase and Acyl-CoA-cholesterol transferase (ACAT) and with increased Microsomal 
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transfer protein (MTTP) expression. Rashid et al [70] also recently demonstrated that PCSK9 
treated Caco2/15 cells also promotes intestinal overproduction of triglyceride-rich apoB 
lipoproteins and increased expression of lipid generating enzymes (FAS, SCD and DGAT2) 
and enhanced activity of MTTP protein providing stability to apoB [70]. This activity of PCSK9 
might enhances the clinical risk of postprandial hypertriglyceridemia 
Conclusively, these recent findings suggests that reducing PCSK9 activity results in 
reduction of apoB expression, less triglyceride rich lipoprotein packaging and secretion due 
to the decrease levels of MTTP and ACAT proteins- eventually leads to better lipid profile. 
PCSK9 monoclonal antibody treatment seems not only as an additive therapy to improve 
statin efficacy but might also reduces the risk of post-prandial hypertriglyceridemia. 
 
Role in Pancreatic beta cells 
Data from clinical phase trials did not present any significant relationship between 
plasma PCSK9 levels and glucose metabolism. However, pancreatic beta cells fully expresses 
PCSK9 and LDL-R.  Recent data from PCSK9-/- mice models indicating hypoinsulinemic, 
hyperglycemic and glucose intolerant phenotypes with increased surface LDL-R 
expression[71], which might overloading the beta cells with circulating LDL and impairing in 
the secretion of insulin. Hypercholesterolemia treatment with PCSK9 monoclonal 
antibodies might require tight surveillance in a longer run.  
 
Role in Kidney 
Nephrotic syndrome patients exhibits higher serum total and LDL cholesterol levels, 
one factor underlying in this due to the acquired LDL-R deficiency[72]. PCSK9 activity was 
later suspected for the cause due to its endogenous production in kidney [52] [30]. This 
might be explained by the results produced from transgenic mice expressing human PCSK9 
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(hPCSK9) especially in the kidney, these mice displayed high plasma PCSK9 levels but with 
its tissue specificity for LDL-R degradation. hPCSK9 originating from kidney of transgenic 
mice virtually contributing in hepatic LDL-R degradation, but no change in adrenal and 
minimal change in its own LDL-R expressions[53]. The reason behind this multifarious role 
of PCSK9 is unknown, however one possibility might be due to the absence of intracellular 
unknown protein(s) targeting or sorting the PCSK9-LDL-R complex to lysosome in kidney and 
adipose tissue.  This due observations can be better hypothesized from a recent study on 
PCSK9-mediated LDL-R downregulation in SV-589 human skin fibroblasts, where PCSK9-LDL-
R complex followed the similar pathway of internalization endocytosis but presented a loose 
association in  early endosome which leads in recycling of LDL-R[73]. However, PCSK9 
endogeneous role in extra-hepatic tissues cannot be neglected and requires further 
scrutiny.  
In humans, plasma from chronic kidney disease (CKD) patients had about 55.52% 
higher PCSK9 than controls[74], which further dropped at normal levels after hemodialysis 
and kidney transplantation. These observations suggests that extra-hepatic expression of 
PCSK9 also contributes in serum cholesterol levels by downregulating hepatic LDL-R, which 
is in line with Zaid et al finding in mice[52]. 
 
1.12 PCSK9 and Atherosclerosis mice models  
PCSK9 role in hypercholesterolemia is very well documented, and this might 
explained more strongly due to hepatic PCSK9 contributions. On the other hand, studies on 
transgenic mice models suggest that PCSK9 gene deletion from mice is not lethal to the mice 
and present normal reproductive ability, they further shows reduction in total plasma 
cholesterol levels (-48%), HDL (-30%) with no change in plasma and hepatic triglycerides and 
hepatic cholesterol levels than WT mice[75]. Conversely transgenic mice overexpressing 
PCSK9 exhibits about 5-15 folds higher circulating LDL-c[67].  
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Adenoviral-mediated expression of human PCSK9 (hPCSK9) in mice results in an 
intermediate LDL-R-knockout phenotype [76]. Parabiosis experiments on mice with and 
without PCSK9 exhibited that PCSK9 act mostly in a paracrine/endocrine fashion [54]. 
 Mice cholesterol transportation system is somehow different from humans, largely 
carried onto HDL, thus reduction in HDL levels in PCSK9-KO mice is due to the effect of highly 
expressed LDL-R mediated clearance of ApoE containing particles.  
PCSK9 also likely to bound with circulating lipoproteins in both WT and LDL-R-KO 
mice models[77], PCSK9 binding with LDL-c was also seen in human normolipidemic 
subjects[78].  
Interestingly, since PCSK9 predominantly secreted by hepatocytes, Liver specific 
conditional PCSK9-KO mice was generated and studied for the lipid metabolism, these 
transgenic mice exhibited about 35% less reduction in total plasma cholesterol levels than 
complete PCSK9-KO mice[67], grounding for the role of extra-hepatic PCSK9.  
 
1.13.  PCSK9 role in cardiovascular diseases (CVDs) 
Plasma PCSK9 levels as a risk factor for future stroke and other CVDs were also 
assessed in few studies, high levels of plasma PCSK9 was found positively associated with 
increased intima-media thickness of carotid artery (cIMT) in normotensive subjects[79] and 
also in hypertensive cohort after adjusting co-variables in multivariable regression 
analysis[80] -. A recent study on relationship of higher plasma PCSK9 levels in patients with 
stable coronary artery disease was observed and further found associated with increased 
cardiovascular events (CVE), hypertension, total cholesterol, fasting triglycerides, 
hypolipidemics drug (Statins), HbA1c, Insulin and C-reactive protein (CRP), however no 
association was found with LDLc or HDL- cholesterol. To be noted, the association between 
plasma PCSK9 and risk of CVE was reduced in a model adjusting for fasting TGs[81] 
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SECTION [B2].  G-PROTEIN COUPLED ESTROGEN RECEPTOR (GPER) ROLE IN CARDIOVASCULAR SYSTEM 
1.14. ESTROGENs (Introduction and Biosynthesis) 
Estrogens are class of endocrine hormones, secreted from ovaries and in lesser 
amounts by the adrenal cortex, placenta and male testes, however often referred as a 
female sex hormone, a small amount of estrogens are also found in men. The term 
“estrogens” refers to all of the chemically similar hormones like estrone (also called “E1” -
most abundant after Menopause), estradiol (also called “E2”- primarily in women’s 
reproductive age) and estriol (also called “E3”-predominant during pregnancy)- [Figure 10]. 
Estrogens are important for sexual and reproduction, mammary gland development, bone 
turnover, metabolism, in addition estrogen role in cardiovascular function is also emerging. 
As from recent reports, endogenous estrogens in pre-menopausal women largely prevent 
the development of coronary artery disease (CAD), peripheral artery disease 
(PAD),Myocardium infarction (MI) and Stroke, partly due to the beneficial effects on blood 
pressure, lipid metabolism and glucose homeostasis while these benefits reverses in post-
menopausal state and in experimental overiectomized animal models 
[82][83][84][85][86][87]. Indeed about 95% of women develop cardiovascular disease after 
menopause when endogenous estrogens are at their lowest levels[88][89][90]. Thus ovarian 
dysfunction (hypogonadism), polycystic ovarian syndrome or surgical menopause before 
natural menopause or even in overiectomized female mice (those mimic the similar 
menopause), all these conditions have been recognized as a major risk factor for accelerated 
atherosclerotic vascular damage. Similarly, genetic mutations in estrogen receptors also 
leads the similar pathophysiological characteristics as represents by estrogen impairment. 
According to current data, postmenopausal women numbers is expected to rise by 1 billion 
worldwide within the next 40 years, and might impose a burden on women’s cardiovascular 
health[91].   In case of estrogen deficiency, natural and synthetic estrogen preparations may 
be prescribed. Estrogen also a component of many oral contraceptives. 
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Biosynthesis of Estrogens :- 
Luteinizing hormone (LH) signaling is the hallmark of estrogen synthesis in ovaries, 
In females, synthesis of estrogens starts in “theca interna” cells on the ovary, by the 
synthesis of androstenedione from cholesterol. Androstenedione is a substance of weak 
androgenic activity which serves predominantly as a precursor for the more potent 
androgens such as testosterone as well as estrogen. This compound crosses the “basal 
membrane” into the surrounding granulosa cells, where it is converted either immediately 
into estrone or into testosterone and then estradiol in an additional step. The conversion of 
androstenedione to testosterone is catalyzed by 17β-hydroxysteroid dehydrogenase (17 β-
HSD), whereas the conversion of androstenedione and testosterone into estrone and 
estradiol, respectively is catalyzed by aromatase enzyme which are both expressed in 
granulose cells. 
Estrogen levels vary throughout the menstrual cycle, with highest at ovulatory 
phase. 
 
Figure 10. Chemical structure of Estrogens 
This figure depict the three major forms of physiological Estrogens. 
[Figure adapted from https://www.kingsrxandwellness.com/know-your-estrogens-and-your-body] 
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1.15. Molecular mechanisms of Estrogen mediated cellular signalling (ERα, ERβ-    
Classical pathway and non-classical pathway) 
Once released from ovaries, estrogen like all steroid hormones, readily diffuses 
across cell membrane and binds and activate estrogen receptors (ERs) which in turn 
modulates the expression of many genes. Estrogen binding to its receptors generally fall 
into two broad categories, genomic or classical pathway and non-genomic or non-classical 
pathways. Classical pathways includes the functions or activity of two cytoplasmic estrogen 
receptors viz ERα and ERβ and they act as a ligand-activated transcription factors that reside 
in the cytosol and translocate into the nucleus upon ligand binding., while G-protein coupled 
estrogen receptor (GPER 30) which is a membrane receptor located onto the endoplasmic 
reticulum and mediates rapid estrogen signalling constitute non-genomic pathway.  
 
(a) Classical pathway and cardiovascular system:- 
The ERα and ERβ receptors constitutes estrogen mediated classical or genomic 
pathway. Estrogen binding to ERα and ERβ results in their translocation into the nucleus, 
where they act as a transcription factors leading to altered gene expressions. ERα and ERβ 
shares extensive structure homology, DNA binding domain of the receptors (ERα and ERβ) 
are the most identical (about 96-97% homologous) and ligand binding domain (LBD) 
sequence also constitutes about 53%- 60% homology between the two’s[92]. However, a 
structure difference is utmost exist between ERα and ERβ in the amino terminal 
transcription control domain, AF-1 through which regulatory binding partners interacts 
[Figure 11]. 
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Figure 11. Structural homology of estrogen receptor ERα and ERβ. 
ER-α and ER-β shares a structural homology as depicted in this figure and can go  
homodimerization or heterodimeration upon activation.[Figure adapted from Roman-Blas et al.  
Arthritis research & therapy 2009. 11:241]. 
ERα and ERβ  carries four functional domains- A DNA binding domain (DBD), a ligand 
binding domain (LBD) and two transcriptional activation functional domain (AF-1 and AF-2). 
The percentage of sharing homology between twos, sites of phosphorylation are given in 
[Figure 11] 
ERα and ERβ targeted by estrogen and mediates several estrogen responsive 
element (ERE) containing genes expression, estrogen binding to ERs initiates at LBD/AF-2 
domain results in ERs conformational change leading to ERs dimerization and translocation 
to the nucleus where binding to consensus estrogen response element (ERE) sites to the 
DNA begins to modulates the ERE-containing genes[93]. The consensus ERE sequence is 5’ 
GGTCAnnnTGACC 3’. 
ERs also binds to non-ERE carrying genes, ERs binding to transcription factors like 
AP1 and Sp1 mediates ERs binding to DNA, which is commonly known as a “transcriptional 
cross talk” mechanism. ERs can also function in a ligand-independent manner, the 
phosphorylation of ER can facilitate ERs binding to ERE in the absence of estrogen[94]. 
Both ERα and ERβ regulates distinct genes expressions in a tissue dependent manner 
[95][96][97][98] largely relies on the differences in co-activators and corepressors in 
different tissues and different levels of the ERα and ERβ. 
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In addition to their differ activity in the tissue dependent manner, both ERα and ERβ 
can differentially behave in the same tissue too[98], in vascular smooth muscle cells, ERβ 
enhances nitric oxide synthase gene expression while it is repressed by ERα[99]. There could 
also be a time-dependent difference in gene expression (few hours until 1 week), as 
suggested by many studies. In vascular tissue, estrogen recruits in a temporal manner 
specific transcription factors that propagate distinct estrogen signalling[100][101]. These 
ERα mediated versus ERβ-mediated differences in gene regulation are likely attributable to 
differential recruitment of corepressor and coactivators. A candidate gene approach studies 
revealed that many estrogen mediated gene expressions (directly or indirectly) involved in 
cardio-protection [102][103], including mitochondrial complex IV[104], GLUT-4[105], 
Connexin 43[106][107], PPAR-gamma1α[108], adenine nucleotide translocator[109], Heat 
shock proteins[110].  
However there are also studies suggesting for gender difference and in pre vs post-
menopausal state[111].  In cardiac myocytes, ERβ is often expresses in a similar fashion 
irrespective to gender, while ERα shows gender specificity[112]. Different stages if 
menstrual cycle in pre-menopausal state also constitute different receptor expressions, ERα 
expression in vascular endothelial cells has been found 30% less during early follicular phase 
when compared with late follicular phase[113] 
 
(b) Non-Classical pathway and cardiovascular system:- 
GPER (alias GPR30) or G-protein coupled estrogen receptor is a seven 
transmembrane-domain G-protein coupled receptor (GPCR), was first cloned at Lund 
University during mid 1990s and nominated as “orphan receptor” due to unidentified 
ligand[114], however for the first time GPR30 de-orphanized in 2005[115], and officially 
designated as GPER by the “International Union of Pharmacology” in 2007[116]. With 
certain contradictory reports[117][118][119] GPER still remained an significant contributors 
of estrogen mediated signalling. In the year 2000, Filardo et al. demonstrated MAP kinase 
(ERK1/2) activation by estrogen in breast cancer cell lines expressing GPR30 but not in cell 
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lines lacking GPR30[120]. Subsequent studies revealed a second phase of GPR30-dependent 
signalling via adenylyl cyclase that resulted in the eventual attenuation of ERK 
activation[121]. During initial years, the localization of GPER was controversial, Thomas and 
colleagues identified GPER as a plasma membrane bound G-protein receptor[122], while 
Revankar et al identified GPER in the endoplasmic reticulum of COS7 monkey kidney 
cells[115]. GPER expression is found in almost all cell types including endothelial cells, 
vascular smooth muscle cells (VSMCs)[123], Nervous system[124], Reproductive 
system[125] and in immune cells[126]-[Figure 12]. 
 
 
Figure 12. Different sites expression of GPER 
GPER protein expresses in several tissues types and triggered signal cascading upon  
ligand binding.[Figure adapted from Barton. M et al, Trends in endocrinology & metabolism. 2015;  
Vol 26; issue 4;  185-192]. 
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1.16. G-protein coupled estrogen receptor (GPER) signalling 
The G-protein coupled estrogen receptor is a seven transmembrane receptor 
located onto the endoplasmic membrane and triggers rapid and transient activation of 
numerous intracellular signalling upon ligand binding. GPER mediated signalling has 
attracted increasing interest in estrogen biology. GPER like other GPCRs, are coupled to 
heterotrimeric G-proteins (α,β and γ subunits) that in turns regulate a plethora of 
downstream signal cascading[127]. As observed for the GPCR mediated responses, the 
activation of epidermal growth factor receptor (EGFR) is a fundamental integration point in 
the biological action triggered by GPER, which in-turn leads to the activation of  extracellular 
signal-regulated kinase ½ (ERK1/2) and phosphoinositide 3-kinase (PI3K)[115][120][128] 
and regulates calcium mobilization[129][130][115] and potassium channels[131]. The 
activated GPER and its downstream signalling pathways mediated pleotropic functions 
among others in the cardiovascular, reproductive, central nervous system, endocrine, and 
immune systems.   
Therefore, GPER is likely to play significant roles in mediating many estrogen-
associated role in body. The role of GPER deficiency revealed from mice model studies, 
where GPER-KO mice exhibited advanced thymic atrophy[132], visceral obesity[129], insulin 
resistance, dyslipidemia[133][134], vasoconstriction and increased vascular smooth muscle 
cell growth[129]-[Figure 13]. 
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Figure 13. Classical and non-classical signalling pathway 
Estrogen binding to receptors of (1) classical or genomic pathway located in the cytoplasm and 
nucleus, activated Estrogen receptors binds to the estrogen response element (ERE) of the genes and initiate 
their transcription.(2) Estrogen also activate membrane bound ER-pathway leads to activate intracellular 
cascading and neighbouring GPCRs (G-protein coupled receptors) and promotes CREB-modulated protein 
transcription. (3) The non-genomic or non-classical pathway majorly defines for GPER pathway resulting in 
gene transcription. [Figure adopted from Cover KK et al; translational Psychiatry.2014 August e.422]. 
 
1.17. GPER activation in vasculature and heart or Cardiovascular system  
Results from several studies indicates for the GPER expression exist in the 
cardiovascular system-A system which was long suspected for the estrogen mediated 
beneficial effect in women in their premenopausal phase, but with unclear mechanism. 
GPER expression in cardiovascular system includes human mammary artery and saphenous 
vein[123]---, human endothelial cells[135], mouse mesenteric resistance arteries[136] and 
bovine pericytes [137].  In mice, a large proportion of cardiovascular GPER expresses in small 
arterial vessels, while in CNS, the receptor is expressed primarily in pericytes and smooth 
muscle cells[138] 
GPER activity has been recently studied in vasculature by using mice models of GPER-
KO, or GPER agonist (G1) and antagonist (G15). G1 Is most potent and commonly used 
agonist in routine lab research, which provide a similar affinity and specificity to the 
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receptor as does by 17β-estradiol (E2) to the GPER[139] G1 treated mice display 
vasodilation and blunting of endothelin-1-mediated vasoconstriction[140] of epicardial 
coronary arteries, and vasodilation and decreased oxidative stress in carotid 
arteries[141],and intracellular calcium in human aortic VSMC exposed to serotonin. A study 
by Martensson et al demonstrated that 9 month old GPER-KO mice exhibits increased mean 
arterial blood pressure (MAP); this is associated with the increased media to lumen ratio of 
second-order mesenteric resistance arteries[136]. Hass et al on the other hand, showed that 
G1 lowers MAP and dilates pre-constricted mesenteric aretries in rats, and that GPER 
deletion abolishes G1 dilation of mouse carotid artery rings, pointing to possible direct 
vascular role of GPER[129], this same group also observed that G1 inhibits proliferation of 
human umbilical vein smooth muscle cells[129] consistent with a growth-inhibitory effect 
via GPER in some cell types[142][143][144], but a growth promoting effect in others[145]. 
 
1.18. GPER activity on lipid metabolism, Atherosclerosis and Inflammation 
Estrogen brings several beneficial effect in early life of females, while post-
menopausal phase loses estrogen benefits, similarly overiectomized mice mimics the similar 
clinical outputs. Several studies are undergoing to know the biological mechanism behind 
the estrogen mediated effects, a recent discovered estrogen mediated GPER pathway is 
now exploring by scientific community. GPER-KO female mice presents impaired glucose 
tolerance, increased blood pressure, decreased HDL and increased LDL and triglycerides 
levels [133] [136], increased activity of the vasoconstrictor endothelin-1 [130] and the 
increased adipose-derived contracting factor (ADCF) and excessive formation of 
perivascular adipose [146] –all these GPER deficient outcomes are the major risk factor 
associated with coronary atherosclerosis and is a clinical phenotypes of patients with 
obesity, insulin resistance or diabetes, these female mice also showed a symptoms of 
hepatic steatosis[147]. Similarly GPER-KO mice under high fat diet also develop 
atherosclerotic plaques with increased plasma LDL levels in both ovary-intact and surgically 
postmenopausal mice[148]. Conversely, activation of GPER inhibits the proliferation of 
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human vascular smooth muscle cells in vitro-an essential protective phenomenon while 
atherosclerosis [129][149], and reduced vascular inflammation involving reduced 
macrophage and T-cell dependent mechanisms [148], treatment with highly selective GPER 
agonist (G1) was effective in reducing atherosclerosis in postmenopausal mice[148], this 
protection was also seen in mice lacking ERα [134], suggesting a powerful contribution of 
GPER in cardiovascular system and a promising therapeutic target.  
 
1.19. Genetic study of GPER and role in blood pressure & cholesterol homeostasis 
Studies of GPER deficiency in human is limited, a recent report on the regulation of 
LDL-c due to the hypofunctional variant (rs1154331; p.P16L) on GPER gene showed higher 
circulating plasma cholesterol levels and high blood pressure in women[150][151]; 
furthermore, experiments performed on HepG2 cells, demonstrated an inhibitory role for 
GPER variant in the regulation of LDL receptor expression[150].  In agreement to the results 
from GPER-KO mice models and the information from GPER variant (rs1154331) studies 
indicates the beneficial role of GPER. In this thesis, we will further see the role of GPER 
rs11544331 variants role in PLIC subjects. 
 
SECTION [B3] IDOL (INDUCIBLE DEGRADER OF LDL-R) ROLE IN LDL-R MODULATION 
1.20. Introduction and biological structure of IDOL 
The IDOL gene originally cloned as MYLIP (myosin regulatory light chain interacting 
protein][152] encodes 445 amino acid protein. Structurally IDOL carries two distinct 
domains: an N-terminal FERM (4.1, Ezrin, radixin and Moesin domain) and C-terminal Ring 
domain (Really interesting new gene)- [Figure 14]. This makes IDOL a unique protein as IDOL 
is the only protein in the human genome that carries both FERM and RING domain in its 
structure. The FERM domain is the member of the ERM (Ezrin, radixin and Moesin) family 
of proteins contributing in interaction between membranes and membrane proteins[153]. 
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The RING domain of IDOL shares structure homology as found in other RING-containing E3-
ubiquitin ligases[154]. 
 
Figure 14. Linear structure of IDOL- protein 
The protein carries N-terminal FERM domain and C-terminal RING domain, both domains are  
separated by a short linker region (from 344 aa uptil 368aa).[Figure adopted from Sorrentino et al.  
Current opinion in lipidology. June 2012, p 213-219]. 
 
1.21. Molecular mechanism of IDOL mediated degradation of LDL-R 
The expression of IDOL protein is mediated via activation of Liver –X receptor (LXR). 
The LXRs are nuclear receptors and their activation is largely relies on the intracellular 
cholesterol levels, higher intracellular cholesterol trafficking forms oxysterol- which act as a 
ligands for LXRs [155]and their activation leads the expression of genes encoding cholesterol 
efflux from cells (like ABCA1 and ABCG1)[156][157], later LXRs was found in regulating LDL-
R activity via IDOL protein which ubiquitinises the receptor at cytoplasmic region and direct 
it to intracellular degradation, hence influences on the cellular uptake of cholesterol [Figure 
15]. Overexpression of IDOL dramatically enhance LDL-R ubiquitination and eventually its 
degradation, while cells (embryonic stem cells) lacking IDOL expressions had more profound  
LDL-R levels[158]. 
Introduction 
35 
 
 
Figure 15. Molecular mechanism of Inducible degrader of LDLR (IDOL) protein 
  IDOL mediated intracellular ubiquitylation of LDL-R leads to lysosomal degradation. 
[Figure adapted from Sorrentino.V et al, Current opinion in lipidology, vol 23(3), June 2012,p213-219]. 
 
 
1.22. GWAS and Population based study on IDOL 
Until recently, the genetic mutation profiling of IDOL gene and their impact on 
cholesterol level was unknown. In last few years, genome wide association studies (GWAS) 
were conducted and have demonstrated various functional point mutations in the region of 
IDOL gene- several of these point mutations were linked with total cholesterol and LDL 
cholesterol levels in different population[159][160]. One of the recent identified SNP of 
IDOL gene which was found associated with high cholesterol levels is rs9370867 (p.N342S). 
This SNP was found in the coding region and allows a non-synonymous change at position 
342aa of the FERM domain in protein chain, the FERM region is essential in order to interact 
with cytoplasmic tail of LDL-R. The enhanced functionality of GWAS identified SNP was 
further validated in Mexican cohort too[9]. In this thesis, we will further see the role of IDOL 
N342S in PLIC subjects. 
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CHAPTER 2.  AIMs OF THE STUDY 
In mice 
(i) To understand the role of PCSK9 protein in carotid atherosclerosis 
development by using “Carotid artery injury model” 
(ii) PCSK9 role in glucose homeostasis 
 
 
In Humans 
(i) Genetic variant study of LDL-R modulators (PCSK9, IDOL and GPER) and their 
effect size on lipid variability, glucose homeostasis and atherosclerosis 
progression. 
(ii) Determination of plasma PCSK9 levels in PLIC subjects and association 
studies. 
(iii) Ecstatic effects of genes over plasma PCSK9 levels. 
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CHAPTER 3. MATERIALS and METHODS 
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SECTION [A]-  STUDIES IN MICE 
SECTION [A1] CAROTID PROGRESSION STUDY IN MICE 
3.1. Genetically modified PCSK9 mice model 
All animal care and experimental procedures were in accordance with the 
institutional guidelines for animal research.  
Mice carrying the PCSK9-wild type and null allele were confirmed by PCR of tail DNA. 
Animals used in our studies were age-matched (littermates), WT (PCSK9+/+) and PCSK9 (-/-
) male offspring produced by 4 consecutive backcross onto a C57BL6/J strain background. 
Male mice were preferred for the experimental studies to reduce the confounding effect of 
female predominant hormones. We use a range of 22-30 grams body weight, and all mice 
were kept in normal chow diet and Diet induced obesity (DIO) diet for specific experiments. 
Mice were housed under controlled light (12 hours light/12 hours’ dark) and 
temperature conditions, and had free access to food and water. 
 
3.2. Aseptic and sterile practices 
As per institutional guidelines, all surgeries were performed under sterile condition 
in a germ-free area of surgical room in animal house facility. All sterile instruments, pre-
disinfected tables and solutions and a sterile surgical field and surgical attire (like, scrubs, 
gloves, surgical gown, head and hair covering cap, facemask, shoe cover etc) have been used 
for surgery.  
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3.3. DNA isolation, primer sequences and Genotyping 
DNA isolation were performed from tail of WT and PCSK9-KO mice, a small piece of 
about 2-3mm above from the tail tip were cut and placed in 1.5ml Eppendorf tube and allow 
to digest with 0.5ml DNA digestion buffer (50mM Tris Hcl pH 8.0; 4mM EDTA pH 8.0; 0.2M 
Nacl and 0.5% SDS), with proteinase K (of 10mg/ml) and placed the tubes for overnight 
incubation at 56˚C. next day, tubes were vortex and centrifuged at 13,000rpm for 10 min, 
supernant were recovered and 0.8ml neutralised phenol/chloroform/iso-amyl alcohol 
(25:24:1) were added under the laminar hood, tubes were vortexed for a while and spin at 
13000rpm for 10 minutes, and the top white layer were collected in fresh 1.5ml Eppendorf 
tube. 0.8ml of 95% ethanol were added for DNA precipitation at room temperature, a final 
centrifugation at 13,000rpm for 10 minutes were given and supernant were discarded. The 
pellet were allowed to dry at room temperature for about 3-4 hours. At the end, 0.1ml of 
de-ionized sterilised water were added to elute the DNA followed by 5 min incubation in 
water bath at 56˚C. 
PCR were performed for PCSK9 gene to confirm the genotypes of the WT and PCSK9-
KO mice. PCSK9 primer details are as follow- (P1- 5’ GAT TGG GAA GAC AAT AGC AGG CAT 
GC 3’;   P2-5’ ATT GTT GGA GGG AGA AGT ACA GGG GT 3’ & P3- 5’ GGG CGA GCA TCA GCT 
CTT CAT AAT CT 3’). WT (653 bp) WT/K0 (653 bp and 320bp) and PCSK9KO (320 bp). 
 
3.4. Lipid measurement by FPLC 
Blood was collected from mice fasted for 4 h. Total cholesterol levels in plasma or 
lipoproteins were assayed by enzymatic methods (Horiba ABX Pentra). Lipoprotein profiles 
were analysed by fast protein liquid chromatography (FPLC- BIORAD- NGC chromatography 
system). Pooled mouse plasma (200 µl) from six mice was loaded onto tandem Superose 6 
columns (Pharmacia LKB Biotechnology, Piscataway, NJ) and eluted with lipoprotein 
separation buffer (154 mM NaCl, 1 mM EDTA and 0.02% NaN3) as described[161].  
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3.5. Serum cholesterol assay  
Blood samples were taken under general anaesthesia by retro-orbital puncture at 
the time of collar surgery and at sacrifice. Serum total cholesterol levels were measured by 
an enzymatic colorimetric assay (Horiba ABX Pentra). 
 
3.6. Perivascular Manipulation- Collar placement in right carotid artery 
Perivascular manipulation were done by placing collar on the right carotid artery of 
22-30gm of WT and PCSK9-KO mice, Left carotid use as a “SHAM” or controls, however left 
carotid artery presents a longer section for intervention and is a choice of control. 
Male C57BL/6 mice and PCSK9−/− genotypes (16-week-old, Charles River 
Laboratories) were used in accordance with the “Guide for the Care and Use of Laboratory 
animals” published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). The schematic diagram of the study design is presented in Figure 17. Mice 
(n=16 C57BL/6 and 16 PCSK9−/−) were maintained on a normal chow diet (Mucedola, Milan, 
Italy) for 9 weeks post-surgery. Food and water were provided ad libitum.  
Briefly, after reaching at 4 weeks age, mice were anaesthetized by the 
intraperitoneal injection of avertin (12µg/gr body weight of 2.5% solution- mother stock:- 
1gm of tribromoethanol + 1ml iso-amyl alcohol; working stock:- 1:40 dilution of stock(eg 
300µl stock + 11.7ml water)) and subjected to perivascular carotid collar placement. Collars 
(length: 3 mm, internal diameter: 0.38 mm, external diameter: 2.2 mm) were made from 
Tygon® tubing and were positioned around the right carotid artery. The contralateral left 
carotid artery was sham-operated to serve as intra-animal control. Following carotid injury, 
the animals were maintained on their normal chow diet for 9 weeks, after which they were 
sacrificed with an overdose of Avertin solution to harvest tissue specimens. Body weights 
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were recorded at the time of collar surgery and at sacrifice. Weight increases were similar 
among the groups (data not shown). 
 
3.7. Histological examination 
After 9 weeks on chow diet post-surgery, mice were anaesthetised intraperitoneally 
by avertin, Tissue samples collected at sacrifice (the collared segment of the right carotid 
artery and the corresponding segment of the contralateral sham-operated artery), both 
sections were fixed overnight in 4% paraformaldehyde at 4˚C, tissues were embedded in 
paraffin blocks as per laboratory protocol, and sections were cut transversally into 5µm size 
in Microtome.  Every 200 m ≈, along the entire length of the tissue specimen (not including 
portions outside – proximal or distal – of the collar), a cross-section was stained with 
hematoxylin and eosin (H and E). Images of H and E-stained sections were obtained with a 
Zeiss Microscope mounted with a digital camera (Nikon Coolpix990) and morphometrically 
analyzed by using the OPTIMAS 6.2 image software (Media Cybernetics, Silverspring, MD, 
USA). The cross-sectional areas of the intima and the media were measured directly; the 
intima/media area ratio (I/M) was determined by dividing the intimal area by the medial 
area. The perimeters of the lumen and the external elastic lamina were recorded and used 
to derive the lumen area and the area surrounded by the external elastic lamina (EEL), 
respectively, using the formula perimeter² (4π)ˉ¹, to normalize for artefacts due to fixation 
or other steps of sample processing, including occasional deformation and potential tissue 
shrinkage; for both parameters, calculated values were higher compared to the original 
measurements (particularly in the case of the thin-walled sham-operated carotids), but 
were significantly correlated (Pearson’s r = 0.712 for lumen area and 0.701 for EEL area; P < 
0.0001 for both correlations). The extent of vascular remodeling was expressed as the 
remodeling index (RI), calculated as the ratio between the EEL area of collared carotid 
arteries and that of the corresponding sham-operated arteries, i.e., RI = EEL area collar/EEL 
area sham. Linear regression analysis using intimal area as the predictor (independent 
variable) and EEL area as the dependent variable was performed for all specimens from 
collared carotid arteries. 
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3.8. Reagents and Antibodies 
DMEM, trypsin EDTA, penicillin, streptomycin, nonessential amino acid solution, FBS 
were from Euroclone (Pero, Milan, Italy). Plates and petri dishes were from Corning 
(Oneonta, New York, USA). PDGF-BB were from SIGMA. Molecular weight protein standards 
were from BIO-RAD Laboratories (Hercules, CA). SDS, TEMED, ammonium persulfate, 
glycine, and acrylamide solution (30%T, 2.6%C) were obtained from BIO-RAD Laboratories. 
BCA assay for determination of protein concentrations was purchased from Thermo Fischer 
Scientific (Waltham, MA). For Western Blot (WB) analysis, the following antibodies were 
used: anti-PCSK9 (Cayman, Tallinn, Estonia), anti-α-tubulin (SIGMA-Aldrich), anti-LDLR, anti-
PDGFR, anti-LRP1 (all from Abcam, Cambridge, UK), and secondary IRDye800 Goat anti-
mouse and anti rabbit (Carlo Erba reagents, Cornaredo Milan, Italy). 
 
3.9. Immunostaining 
 Immunostaining with cell type specific primary antibodies and Picrosirius red stain 
were performed on serial sections adjacent to those selected for morphometry. To detect -
smooth muscle actin (-SMA)-positive vascular SMCs, sections were incubated with an anti--
SMA mouse monoclonal antibody (1:200, Sigma, clone 1A4) followed by the MOM kit 
(Vector Labs) to minimize nonspecific staining, and extrAvidin FITC (1:100, Sigma). For 
detection of monocytes/macrophages and polymorphonuclear leukocytes, sections were 
blocked for endogenous peroxidase activity and for non-specific staining and incubated with 
Mac3 rat mAb (1:10; PharMingen) or MCA771GA rat mAb (1:200, Serotec), respectively; 
sections were then incubated with an avidin-biotin-peroxidase kit (Vectastain ABC Elite, 
Vector) and visualized with 3,3’-diaminobenzidine (Sigma), followed by counterstaining 
with 10% Mayer’s hematoxylin. To detect intimal collagen, sections were stained with 
Picrosirius red (Direct red 80; Sigma) and analyzed under white light. Positive areas were 
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determined by computer assisted image analysis (OPTIMAS 6.2), and related to total intimal 
surface area. 
 
3.10. Real time Primers (mice) 
SREBP-1a-fwd (5’-TAG TCC  GAA  GCC  GGG  TGG  GCG  CCG  GCG  CCA T-3’), SREBP-
1a-rev  (5’-GAT  GTC  GTT  CAA  AAC  CGC  TGT  GTG  TCC  AGT  TC-3’), IRS1- Fwd (5’ CCA GCC 
TGG CTA TTT AGC TG – 3’), IRS1- rev (5’ CCC AAC TCA ACT CCA CCA CT-3’), IRS 2- Fwd(5’ GTA 
GTT CAG GTC GCC TCT GC-3’), IRS-2 rev (5’ CAG CTA TTG GGA CCA CCA CT-3’), GLUT4 Fwd(5’ 
CAT GGC TGT CGC TGG TTT CT-3’), GLUT4 rev(5’ GCA TCC GCA ACA TAC TGG AA-3’), RESISTIN 
Fwd (5’ CTT TCA TTT CCC CTC CTT TTC CTT-3’), RESISTIN rev(5’ AGT CTT GTT TGA TCT TCT 
TGT C-3’). 
 
3.11. Tissue Explants and Processing 
After 9 weeks on chow diet post-surgery, mice were anaesthetised intraperitoneally 
by avertin (12 µl/gr body weight of 2.5% solution), Tissue samples collected at sacrifice (the 
collared segment of the right carotid artery and the corresponding segment of the 
contralateral sham-operated artery), both sections  were fixed overnight in 4% 
paraformaldehyde at 4˚C, tissues were embedded in paraffin blocks as per laboratory 
protocol, and sections were cut transversally into 5µm size in Microtome for morphometric 
examinations. 
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3.12. VSMC isolation, proliferation and migration assay 
Aorta from WT and PCSK9-KO mice operated collar surgery were explanted and 
cultured to grow VSMC in DMEM high glucose medium with glutamine and antibiotics 
(Penicilin and Streptomycin) and 10% FBS. 6-14 passages primary cells were used for 
studying the VSMCs phenotypic characteristics. Proliferation assay were performed by 
seeding 10,000 cells in each well of slide provided by company and cells were counted in 
iCelligence machine (ACEA Biosciences Inc, San Diego CA, USA). VSMCs migration assay were 
performed in Boyden chamber and using polycarbonate membrane [Biomap, Milan, Italy]. 
The polycarbonate membrane coated with a 0.1mg/ml of type-I collagen solution (Purecol, 
Nutacon BV, Leimuiden, The Netheroland) in 0.1M acetic acid at 37°C, and lower 
compartment of Boyden chamber were filled with DMEM media in the absence or presence 
of PDGF-BB and upper compartment were used for VSMCs suspension of PCSK9-WT and KO 
(10⁶ cells/ml). The chamber was incubated at 37°C for 6 hours, membrane was stained with 
Diff-Quik staining set (Biomap, Milan, Italy) and transmigrated cells were counted in four 
random high-power field (HPFs) under high magnification (20X). 
 
3.13. Western blot analysis 
The cultured VSMCs were washed twice with sterilized PBS and lysed with lysis 
buffer (50mM Tris pH 7.5, 150mM Nacl, 0.5% Nonidet-P40, containing a protease and 
phosphatase inhibitor cocktails (Sigma Aldrich, Milan, Italy)). The cells were collected in 
1.5mL Eppendorf tube and sonicated. Tubes were placed in water bath for 5 minutes and 
samples were loaded onto polyacrylamide gene for protein separation, the separated 
protein from gel were transferred to nitrocellulose membrane (GE- Healthcare little 
Chalfont, Buckinghamshire, UK) and subsequently immunoblotted by primary antibody 
followed by secondary fluorescently labelled antibody and bands were acquired with the 
Odissey FC system (LI-COR). 
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SECTION [A2] TO STUDY PCSK9 ROLE ON GLUCOSE HOMEOSTASIS:- 
3.14. Glucose tolerance test (GTT) 
Our initial goal to know the PCSK9 role in obesity and insulin resistance, for that 
purpose, mice were stressed by DIO diet (diet induced obesity) to get the obese and insulin 
resistance phenotype in both WT and PCSK9-KO mice. 2 months old mice of both the groups 
were kept on DIO diet for 12th and 20th week. At the end of 12th week and 20th week post-
inception- Glucose tolerance test (GTT) were performed by intraperitoneal injection of 
glucose. The procedure was followed as given below:- 
Mice were kept in overnight fast of about 12-16 hours, only water were supplied 
before GTT. Next day each mice weight were measured and recorded, 20% glucose solution 
in sterile PBS were prepared (2g of glucose/Kg body mass) for intraperitoneal (IP) injection 
[volume of IP glucose injection (µl) = 10 x body weight (gm)].  Blood (≈5µl) from mice tail 
were collected at time 0 (pre-glucose injection) and 15, 30, 60, 90 and 120 minutes (post 
glucose injection) and placed on the glucose test strip of the blood glucose and reading were 
recorded. At the end of experiment, mice were kept back on fresh cages with the food and 
water. 
 
3.15. Insulin tolerance test (ITT) 
Mice were kept overnight fast, and weight were recorded prior to insulin injection. 
The 1mU/10µl solution were prepared from stock of 100 IU insulin solution in sterile PBS 
and injected 30mU insulin in mice. Blood glucose were measured as stated before at time 0 
(t0- prior to insulin injection), and 15, 30, 60, 90 and 120 minutes (post glucose injection) 
and placed on the glucose test strip of the blood glucose meter (Accuchek Inc.) and reading 
were recorded. At the end of experiment, mice were kept back on fresh cages with the food 
and water. 
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3.16. Hepatic- Gene Expression study 
Total RNA was extracted from PCSK9 WT and KO mice of DIO and SFD dietary group. 
RNA was extracted by using Nucleospin RNA columns (Macherey-Nagel GmbH & Co.).  1 μg 
of RNA were used to get cDNA using the IScript cDNA Synthesis kit (BioRad, Milan, Italy). 3 
μL of cDNA were amplified by real-time quantitative PCR with 2X MAXIMA SYBR 
Green/Fluorescein qPCR mastermix (Carlo Erba Reagents, Cornaredo, Italy). The specificity 
of the Sybr green fluorescence was tested by plotting fluorescence as a function of 
temperature to generate a melting curve of the amplicon. Each sample was analyzed in 
duplicate using the CFX Connect Real Time detection system (BioRad, Milan, Italy). The 
primers used are the following:  
SREBP-1a-Fwd (5’-TAG TCC  GAA  GCC  GGG  TGG  GCG  CCG  GCG  CCA T-3’), SREBP-
1a-rev  (5’-GAT  GTC  GTT  CAA  AAC  CGC  TGT  GTG  TCC  AGT  TC-3’), IRS1- Fwd (5’ CCA GCC 
TGG CTA TTT AGC TG – 3’), IRS1- rev (5’ CCC AAC TCA ACT CCA CCA CT-3’), IRS 2- Fwd (5’ GTA 
GTT CAG GTC GCC TCT GC-3’), IRS-2 rev (5’ CAG CTA TTG GGA CCA CCA CT-3’), GLUT4 Fwd 
(5’ CAT GGC TGT CGC TGG TTT CT-3’), GLUT4 rev (5’ GCA TCC GCA ACA TAC TGG AA-3’), 
RESISTIN Fwd (5’ CTT TCA TTT CCC CTC CTT TTC CTT-3’), RESISTIN rev (5’ AGT CTT GTT TGA 
TCT TCT TGT C-3’), Adiponectin Fwd 5’(AAC GTC ATC TTC GGC ATG ACT 3’), Adiponectin Rw 
5’ (GCT CAG GAT GCT ACT GTT GCA A 3’), PCSK9 Fwd 5’-(AGG TGG AGG TGT ATC TCT TAG 
ATA CCA 3’), PCSK9 Rw5’(CGC TGT TGA AGT CGG TGA TG3’). 
 
3.17. Statistical Analysis 
Data are presented as mean ± SD, statistical analysis was performed using student 
t-test or ANOVA when appropriate to analyse statistically significant differences between 
groups. For this study P<0.05 was considered as significant. 
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SECTION B. IN HUMANS:- 
3.18. PLIC COHORT (Progression of lesion in intima-media of carotid artery) and 
selection criteria. 
A cohort of 2141 subjects attending the Atherosclerosis Centre in Bassini Hospital, 
Department of Pharmacological and Biomolecular Sciences (University of Milan, Italy), were 
recruited for the PLIC study. The PLIC study was approved by the Ethics Committee of the 
University of Study of Milan (approved on 06-02-2001 SEFAP protocollo n°0003/2001), all 
participants signed a written informed consent. The investigation was performed in 
accordance with the principles of the Declaration of Helsinki. This project is a study designed 
to investigate the presence and progression of atherosclerotic lesions and intima media 
thickness (IMT) in the carotid artery of a large local cohort in relation to the major 
cardiovascular disease risk factors. Exclusion criteria were use of hypolipidemic drugs (esp 
in PCSK9 studies), presence of liver or kidney disease, thyroid dysfunction. A total of 1110 
subjects for PCSK9, 1384 subjects for IDOL and 1405 subjects for GPER studies were selected 
for the study.  
 
3.19. Blood collection, DNA isolation and Lipid profiling  
Blood samples were collected after an overnight fast from all subjects enrolled in 
the PLIC study. Genomic DNA was extracted from buffy coat samples using the Flexigene 
DNA kit (Qiagen, Milan, Italy) according to the manufacturer’s instructions and stored at -
80˚C until use. Lipid profiling (LDL, total cholesterol, HDL, Triglycerides, ApoA1, ApoB, non-
HDL, remnants etc) were assessed by kit 
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3.20. Genotyping by allelic discrimination assay (PCSK9 R46L, IDOL N342S, and 
GPER P16L) 
Genotyping for the PCSK9-R46L (rs11591147; c.G5428; p.R46L)), IDOL (rs9370867; 
c.G1025A, p.N342S) and GPER (rs11544331; c.C47T; p.P16L) was performed on 5 μL of DNA 
(10–200 ng of DNA), using a TaqMan allelic discrimination test (Applied Biosystem) to 
evaluate or validate the role of these respective SNPs in lipid profile and atherosclerosis 
progression. 
3.21. Measurement of Carotid Intima media thickness by Ultrasonography 
High resolution B-mode ultrasonography of carotid Intima-Media Thickness (c-IMT) 
with a linear ultrasound probe (4.0–13.0MHz frequency, 14X48 mm footprint, 38 mm field 
of view) was performed (Vivid S5 GE Healthcare1, Wauwatosa, WI, USA). The determination 
were performed by a single sonographer, blinded to the subject’s identity (intra‐class 
correlation = 0.812, n = 30). All the measurements were done off-line using the software 
provided by the instrument. The protocol involved the common carotid artery (CCA) (30 mm 
proximal to the carotid bulb), the carotid bulb and internal carotid artery (ICA) at both sides. 
The intima-media thickness (IMT) was assessed at the far wall as the distance between the 
interface of the lumen and intima, and the interface between the media and adventitia in a 
standardized number of points. The maximal IMT was recorded and averaged for the left 
and right sides of the CCA (30 mm proximal to the carotid bulb), the carotid bulb, the ICA. 
Presence of extra-cardiac atherosclerotic vascular involvement was determined with 
presence of focal plaques (> 1.3 mm in longitudinal resolution, lateral or medial angle) 
and/or diffusive mean IMT > 1.3 mm (in longitudinal resolution, lateral or medial angle). The 
protocol involved the determination of the Left Ventricular Mass (LVM) assessment. The 
measurements were performed by two dimensional guided M-mode echocardiography 
from the parasternal window using an M-mode color-Doppler (Vivid S5 GE Healthcare1, 
Wauwatosa, WI, USA) (1.4–4.0 MHz frequency, 19.3X27.6 mm footprint wide-band phased 
array transducer). Left Ventricular Mass (LVM) was calculated with Devereux’s formula, 
according to guidelines. The definition of cardiovascular events (CVEs) included coronary 
heart disease (CHD), such as acute myocardial infarction (AMI), acute coronary syndromes, 
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acute and chronic heart failure (New York Heart Association class II and III); peripheral artery 
disease (PAD) and cerebrovascular events, such as stroke, transient cerebral ischemic attack 
in the previous 6 months, and other vascular complications (including diabetic foot ulcers). 
In addition having undergone major surgery was included in this definition (i.e.: carotid 
thromboarterectomy, percutaneous coronary angioplasty, arterial angioplasty or arterial 
by-pass of the lower limbs, coronary by-pass and amputations). Cardiovascular risk was 
defined in accordance to the Progetto Cuore individual risk score, for the Italian population 
as described. 
 
3.22. Plasma PCSK9 levels measurement 
Blood samples were collected after an overnight fast from all PLIC subjects and 
plasma was separated and stored at -80 until use. Plasma PCSK9 levels were measured by 
using AlphaLISA kit commercially available from PerkinElmer Company (AL270C-500 Assay 
points). 
A lyophilized hPCSK9 standard (0.3 µg) reconstituted in 100µL of distilled water-as 
per company instructions. Further serial dilutions for the standard curve were made in FBS 
ranging from 3 x 10⁵uptil 1pg/ml and were made freshly for each run. All kit components 
were stored in the dark at +4°C, and reconstituted analyte (hPCSK9) were stored at -20°C. 
1:30 dilutions of human plasma in FBS were made to analyze the plasma PCSK9 levels, 
readings were taken from alphaELISA reader (Perkin Elmer-Envision 2101) for each intra- 
and inter-assay run. 
In an AplhaLISA assay, Donor beads conjugated streptavidin binds with a biotinylated 
anti-analyte antibody while AlphaLISA acceptor beads conjugated with another anti-analyte 
antibody. In the presence of the analyte, the beads come into close proximity leads the 
excitation of the donor beads. Upon excitation, donor beads releases a singlet oxygen 
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molecules which brings a cascade of energy transfer in the acceptor beads. All readings were 
taken at 615nm. 
 
3.23. Statistical Analysis 
Statistical analysis of data was performed using SPSS® v.21.0 for Windows® (IBM 
Corporation®, Chicago Illinois, USA) program. Values are shown in mean ± SEM and 
statistically relevant differences were considered for p values < 0.05. 
 
SECTION [C] EXPERIMENTS FOR IN-VITRO ANALYSIS 
3.24. Isolation of human peripheral blood mononuclear cells (PBMC) 
About 15ml blood from median cubital vein of PLIC subjects (for IDOL- GG and AA 
carriers ; for GPER- CC and TT carriers)were withdrawn and collected in sterile blood 
collection tube containing EDTA. Mixing were done immediately to avoid blood coagulation. 
Blood was diluted 1:3 in phosphate buffer saline (PBS) (15ml) then layered onto 4ml of Ficoll 
Hipaque (Amersham) and centrifuged at 1500rpm for 35 min. PBMC were removed from 
the interface and washed twice in PBS before being re-suspended in RPMI-1640 medium 
supplemented with penicillin (50U/ml), streptomycin (50µg/ml), L-glutamine (mM) and 10% 
FBS. PBMC were counted and 2x10⁶ cells were plated in 6 well plates and incubated for 2 
hours in a humified atmosphere (37˚C, 5% CO2). Non-adherent cells were removed with 
four rinses of PBS and attached monocytes cultured for 7 days to obtain monocyte-derived 
macrophages. 
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3.25. LDL preparation and macrophage LDL uptake assay 
LDL (density 1.019–1.063 g/ml) were obtained from freshly isolated human plasma 
from healthy volunteers by preparative ultracentrifugation in KBr gradient, dialyzed versus 
PBS containing 0.01% EDTA and sterilized by filtration. Protein content was determined by 
the colorimetric Lowry assay, using BSA as a standard. We then used a flow-cytometry assay 
to evaluate LDL uptake by using fluorescently labelled LDL, as widely and robust assay 
currently used for the investigation of LDLR function.1mg of LDL was labelled overnight at 
4°C in 1 mL PBS containing 0,5mg/mL of 3,3′-dioctadecyloxacarbocyanine perchlorate (DiO) 
(stock solution 5mg/mL in dimethylformamide) (Sigma Aldrich, Milan, Italy). DiO-LDL were 
then isolated again by ultracentrifugation in KBr gradient and the excess of fluorescent 
probe and KBr salt was removed by dialysis versus PBS containing 0.01% EDTA. LDL were 
sterilized and the protein content determined as previously described. Monocytes-derived 
macrophages were washed with PBS then incubated with 10µg/mL of DiO-LDL in RPMI 
without serum. After 2 hours cells were washed three times with PBS, gently scraped off 
and collected in tubes for flow citometry analysis. Cells were immediately analyzed using a 
FACSCalibur flow cytometer (BD Biosciences) and CellQuest software. 
 
3.26. Gene expression analysis (Real time PCR) 
Total RNA was extracted from monocytes-derived macrophages and 1 μg of RNA 
underwent reverse transcription using the IScript cDNA Synthesis kit (BioRad, Milan, Italy). 
3 μL of cDNA were amplified by real-time quantitative PCR with 2X MAXIMA SYBR 
Green/Fluorescein qPCR mastermix (Carlo Erba Reagents, Cornaredo, Italy). The specificity 
of the Sybr green fluorescence was tested by plotting fluorescence as a function of 
temperature to generate a melting curve of the amplicon. Each sample was analyzed in 
duplicate using the CFX Connect Real Time detection system (BioRad, Milan, Italy). The 
primers used are the following:  
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18S: Fw 5’-CGCAGCTAGGAATAATGGAATAGG-3’, Rw5’- CATGGCCTCAGTTCCGAAA-
3’; LDLR: Fw 5’- GTGTCACAGCGGCGAATG -3’, LDLR Rw 5’- CGCACTCTTTGATGGGTTCA -3’. 
IDOL: Fw 5’- GATAACAGAGACGCACGCATTC -3’, IDOL Rw 5’- CCCTTCAAGTCACGGCTATACTG 
-3’, PCSK9: Fwd 5’-CCT GCG CGT GCT CAA CT3’. PCSK9 Rw 5’ GCT GGC TTT TCC GAA TAA ACT 
C 3’.
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Chapter 4. RESULTS 
 
SECTION [A]. STUDIES IN MICE MODEL 
 [SECTION- A1] To Assess the Carotid atherosclerosis progression in PCSK9 WT/KO 
mice by using carotid artery injury model---------------------------------------------------- [4.1 – 4.4] 
[SECTION A2] To study the role of PCSK9 in Glucose homeostasis by using nutrition 
based modification model-------------------------------------------------------------------------[4.5 – 4.8] 
 
 
SECTION [B]. STUDIES IN HUMAN  
 
 [SECTION-BI] PCSK9 R46L (LOFs) role in lipid homeostasis and Plasma PCSK9 levels in PLIC 
subjects and association studies--------------------------------------------------------------[4.9 – 4.17] 
[SECTION-B2] GPER (p.P16L) polymorphism and association studies----------------[4.18- 4.21] 
[SECTION-B3] IDOL (p.N342S) polymorphism and association studies--------------[4.22 – 4.25] 
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SECTION [A] STUDIES IN MICE MODEL 
SECTION-A1 STUDY OF PCSK9 ROLE IN NEO-INTIMA FORMATION IN CAROTID ARTERY INJURY MODEL 
(CAIM) 
4.1. Serum cholesterol levels, LDLR expression and lipoprotein fractionation 
profiling 
We first examined whether the secreted form of PCSK9 can reduces the levels of 
LDLRs, as shown in [Figure 16]  the number of cell-surface LDLRs declined by approximately 
60% in PCSK9-WT cells than PCSK9-KO cells- [Figure 16-A]. Not only LDLR but PCSK9 has 
ability to reduce the expression of LDLRs like family members like LRP1, VLDLRs and ApoER2 
(Data not shown). 
We further analysed cholesterol levels (by enzymatic kit) and the lipoprotein profiles 
by fast protein liquid chromatography (FPLC), in mice without collar surgery and with 
surgery. In both the models, the lipoprotein fractionation profile was similar, comparison to 
PCSK9-WT mice, PCSK9- KO mice had about 71% less plasma cholesterol levels and about 
50% less HDL (as measured by FPLC) particles, likely by enhanced clearance of ApoE 
containing HDL particles due to reduced degradation of surface LDLR –[Figure 16-B]. 
 
Figure 16. LDLR expression and Lipoprotein levels in PCSK9 WT and KO mice 
(A) LDLR expression levels in the presence and absence of PCSK9 in primary hepatocytes  
(B) Lipoprotein fractionation in PCSK9 WT and KO mice 
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4.2. PCSK9 mice presents accelerated neo-intimal hyperplasia in carotid artery 
injury model  
We next aimed to investigate the pleotropic role of PCSK9 in carotid atherosclerosis 
progression, we used the pre-established settings of our in-house developed collar-
technique, based on the perivascular placement of a plastic cuff around the right common 
carotid artery, and atherosclerosis progression is studied by evaluating the neo-intimal 
hyperplasia in response to vascular injury. 16 week old littermates of PCSK9 WT and KO 
were subjected to perivascular carotid collar placement and fed with normal chow diet upto 
9 months post-surgery-[Figure 17]. Upon sacrifice, morphometric analysis were performed 
on the right carotid specimens (n=16 animals per group).  
 
Figure 17. Schematic planning of carotid injury model :-  
Perivascular manipulation was initiated by placing collar on right carotid artery of 16 week old mice  
(n=15 per group) and followed for 9 week post-surgery. 
 
In both PCSK9-WT and KO mice, collared carotid arteries showed the formation of a 
intimal lesions that invaded the lumen region with different extent, in contrast, no neo-
intima thickening was apparent in sham-operated carotid arteries and no anatomical 
differences was apparent between the two strains [Figure 18-A] . Morphometric analysis 
revealed about 50% reduction of neo-intima media thickness in PCSK9-KO mice when 
compared with WT strain (23.955±1.832 µm2 vs 12.344±1.668 µm2 for PCSK9-WT and 
PCSK9-KO respectively; P=0.049) or intima/media ratio (0.473±0.073 vs 1.380±0.175; for 
PCSK9-WT and PCSK9-KO respectively; P=0.024 (Figure 18-Figure 18B]. These differences 
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were associated to a tendency of a higher lumen area in PCSK9-KO mice vs PCSK9-WT mice 
(30.194±4.324 µm2   vs 18.283±1.912 µm2 respectively), however, this difference were found 
statistically insignificant. 
 
 
 
 
 
Figure 18.  Morphometric analysis of Carotid arteries of WT and PCSK9-KO mice   
post-surgery 
(A) Histologic appearances of carotid artery of control vs experimental mice of PCSK9 WT and KO  
mice.  (B) Quantitative analysis of lumen area and intima-media ratio of carotid artery 
 
4.3. Molecular characterization of carotids of CAIMs 
We further examined the contractile ability of VSMCs cultured from respective 
carotids of PCSK9-WT and KO mice, Immunostaining with anti α-smooth muscle actin (α-
SMA) antibody showed that carotid lesions of PCSK9-WT mice had higher relative SMCs 
accumulation than PCSK9-KO (21.0±7.56 % vs. 10.7±1.97 % respectively; P<0.05) [Figure 19-
A]. Analysis under polarized light of picrosirius red stained specimens, showed a higher 
relative collagen accumulation in PCSK9-WT mice (18.38±7.90 % vs. 10.45±9.11 % 
respectively; P<0.01) [Figure 19-B], while no difference in macrophage content was 
detected, by immunostaining with anti F4/80 antibody, between the two groups.  
A B 
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Figure 19. Immuno-fluorescence staining to study VSMCs phenotypes in controls  
and operated carotids of PCSK9 WT and KO mice. 
 
4.4. Role of PCSK9 in vascular smooth muscle cells (VSMCs) phenotypes 
We cultured aortic SMCs from PCSK9-WT and KO mice to study the role of PCSK9 on 
neo-intimal hyperplasia. No PCSK9 protein were detected in VSMCs of PCSK9-KO mice, as 
expected, while SMC from PCSK9-WT mice had visible PCSK9 occurrence, this difference was 
associated with increased levels of the LDLR in knock-out cells.  At passage one after 
isolation, the expression of phenotypic markers were determined by quantitative RT-PCR 
reaction. SMCs from PCSK9-KO  line expresses higher levels of α-smooth muscle actin (α-
SMA) and lower levels of both caldesmon and collagen type-Ia1. In contrast, no differences 
were found on SM22α expression [Figure 20]. 
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Figure 20. Vascular smooth cells phenotypic markers:- Gene expression profiling of  
vascular smooth muscles cell cultured from PCSK9 WT and PCSK9-KO mice. 
All abovementioned proteins are normalized with β-actin and p-value were  
considered significant if found <0.05. 
 
We next examined the proliferation pattern among the mice strains, Cell 
proliferation rate were assessed by using iCelligence real time monitoring instrument 
[Figure 21-A] , VSMCs were seeded (about 10,000 no. of cells/well) with 10% FBS and 
proliferation were detected in each 3rd and 6th day post-inception. PCSK9-KO mice had about 
46% less proliferation rate than the WT mice (57.3 ± 2.1 hr  vs 106.3 ± 4.5 hr respectively)- 
[Figure 21-B], while the SMCs from PCSK9-WT continuously grown up to 120 h after 
stimulation (Figure 21-C).  
 
Figure 21. Vascular smooth muscle cell proliferation profile.  
 (A)-iCeilligence instrument with the graphical scheme of experiment set on the machine. (B) Equal  
amount of VSMCs (n=10,000) from PCSK9 WT and KO were seeded with 10% FBS and followed the  
growth uptil 120 hours. (C) Quantitative analysis of cell growth at Day 0 and Day 6 from both the  
group. 
Results 
59 
 
Similarly, when studied the migration profile of VSMCs derived from PCSK9-WT and 
KO mice by using by using Boyden chamber chemotaxis assay and the PDGF-BB as a 
chemotactic agent, revealed that VSMCs of PCSK9-WT had higher migration towards PDGF-
BB, and the migration pattern were increased as increases the PDGF-BB concentration 
[Figure 22], while VSMCs from PCSK9-KO mice expresses lower migratory profile. 
Taken together, our data suggest that PCSK9 deficient mice shows less neo-intimal 
hyperplasia in response to perivascular carotid injury, probably might be due to the less 
efficient dedifferentiating phenotype switch of vascular smooth cells.  
 
Figure 22. VSMCs migration profiling. 
(A) A Boyden’s chamber consist of upper and lower compartment and middle space  
for polycarbonate membrane. (B) The difference in migration profile between PCSK9-WT and KO 
derived VSMCs. 
 
[SECTION A2] PCSK9 ROLE IN GLUCOSE HOMEOSTASIS:- RESULTS FROM GLUCOSE TOLERANCE TEST 
(GTT):- 
The objective of this study was to determine the role of PCSK9 in glucose 
homeostasis by using or comparing the glucose absorbance ability in WT and PCSK9-KO mice 
upon intra-peritoneal glucose challenge (2mg/kg, diluted in sterilised PBS).  These mice 
were nutritionally modified and supplied with a high fat rich diet [or DIO-diet (Diet induced 
obesity)] to induce obese phenotype [DIO diet- 24% Protein (gm), 41% Carbohydrate (gm) 
and 24% Corn oil (gm); or 20% protein (kcal), 35% Carbohydrate (kcal) and 45% corn oil 
Results 
60 
 
(kcal)] and subsequently assessed for glucose tolerance test and insulin induced glucose 
absorbance at different time points during the following 2 hours. 
 
4.5. Body weight of PCSK9 strains in nutrition modified model (DIO-diet vs SFD diet)  
All mice of more than 21-22gm in weight at Day- 0 were used for diet induced 
modification uptil week 20th. We first evaluate whether PCSK9 deficiency exacerbate weight 
gain and/or obesity in response to high fat diet. 
Weight were measured at time 0 (week-0) prior keeping on diets and followed their 
weight in every week uptil the end of diet-cycle of 20 week. No significant weight gain were 
observed between the mice strains on DIO-diet [Figure 23]. 
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Figure 23. Weight Gain of PCSK9 WT vs KO mice of DIO diet 
Weight of mice from each dietary group were measure since inception. This figure represents the  
weight gain status between the genotypes per DIO diet. Values are in Mean ± SEM. 
 
 
 
 
4.6. Lipid levels in nutrition modified model 
8 weeks old mice of WT and PCSK9-KO were stressed with DIO (diet induced diet) 
diet to generate the obese phenotype, and compared with the normal fed control SFD diet 
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(standard fat diet) for 20 week. Prior to sacrifice, plasma cholesterol and triglycerides levels 
were measured in both the strains. PCSK9-KO mice had about 25.33% less cholesterol than 
WT mice from DIO-diet group (values in Mean ± SEM ;  92.16 ± 4.77  vs  123.43 ± 5.29 
respectively; p=0.001), while there was no difference found for triglycerides levels 
between the PCSK9 WT and KO groups (values in Mean ± SEM ;  62.81 ± 7.46  vs  66.81 ± 
3.81 respectively; p=0.66)-[Figure 24].  
 
 
Figure 24. Plasma total cholesterol and triglyceride levels determination between  
the PCSK9 genotypes kept on DIO diet 
. 
4.7. PCSK9 deficiency leads to hyperglycemic and hypoinsulinemic phenotypes   
Mice were fed with SFD (11% energy by fat) and DIO diet (45% energy by fat) for 20 
week and IPGTT (intraperitoneal glucose tolerance test- 2mg/kg glucose diluted in dterilised 
PBS) and IPITT (intraperitoneal insulin tolerance test-1mU/10µl) were performed at two 
checkpoints of 12th week and 20th week of post-inception. Mice were kept overnight fasting 
before GTT, intra-peritoneal glucose challenge to both the dietary group (DIO and SFD) 
revealed a moderate but significant glucose resistance in PCSK9-KO mice than PCSK9-WT 
mice at/after 20 min of glucose challenge-[Figure 25-A and B], at 12th week and also after 
20th week post-inception of respective diets [Figure 25-Figure 25C & D]. We further choose 
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to determine the glucose intolerance between the genotypes with same dietary group (esp 
for DIO diet) and analysed for the glucose clearance at different time points (0, 20, 40, 60 
and 120 min) of PCSK9-WT and KO mice from DIO diet group, the phenotypes of PCSK9-KO 
mice resembles with the significant elevation of plasma glucose levels immediately after 20 
min of glucose challenge than PCSK9 WT of DIO diet group [Figure 25-Figure 25E & F], and 
the comparable elevation remain statistical significant upto 120 min post glucose challenge. 
However, the cause of this difference in glucose absorbance was not clear, therefore, we 
further examine the insulin sensitivity test to know whether this difference is due to the lack 
of adequate studied model or beta-cell impaired function, or any other confounding factors. 
 
Figure 25. Glucose tolerance test 
 Blood glucose levels after intraperitoneal injection of glucose (2g/kg) in WT and PCSK9-KO mice  
following check points at time (0, 20,40 60 and 120 min) in WT and PCSK9-KO mice fed a SFD(standard  
fat diet) and DIO (Diet induced obesity) diets for 20 weeks. Results are shown in Means ± SEM.  
*p<0.05 considered as statistical significant for SFD vs DIO diet in WT mice and KO mice as well as  
between KO vs WT for DIO and KO vs DIO for SFD diets. 
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Therefore, we challenged the mice (9 hr fasting) of both groups (DIO and SFD diets) 
with insulin (injected 30mU from intra-peritoneal route), and glucose levels were checked 
at different time points (0, 20, 40, 60 and 120 min). No difference in glucose absorbance 
upon insulin injection were observed. It appears that pancreatic beta cells presents 
impaired section of insulin in PCSK9-KO mice [Figure 26]. 
 
Figure 26. Insulin stimulated glucose disposal rate test. 
Glucose disposal rate were measured between the genotypes of different dietary sets 
 
4.8. Hepatic gene expression profiling of PCSK9 mice (DIO and SFD diets) 
We further investigated the possibility of insulin resistance between the strains of 
both the dietary groups. The ex-vivo liver gene expression studies were performed in both 
the group, and as expected, PCSK9-KO mice of either of the dietary group(DIO and SFD) did 
not show any difference in hepatic insulin receptors (IRS1 and IRS2) expressions than Wild-
type mice [Figure 27]. The glucose disposal rate between the genotypes (WT vs KO) upon 
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insulin injection was similar, while it was not true when only checked for glucose intolerance 
by performing only Glucose tolerance test (GTT), our results indicate that the difference in 
glucose disposal between the WT and KO mice upon dietary stress might be due to the 
impaired insulin secretion from pancreatic beta-cells in PCSK9-KO mice. 
  
Figure 27. Dietary effect on hepatic gene expression.  
Hepatic lipid related genes were evaluated in both PCSK9-WT and KO mice of DIO-diet group 
 
[SECTION B] STUDIES IN HUMAN 
[SECTION-B1] PCSK9 ACTIVITY ON LIPOPROTEIN AND ATHEROSCLEROSIS  
PROGRESSION 
4.9. Background of selecting PCSK9 R46L and plasma PCSK9 levels study 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) protein has been emerged as 
a promising therapeutic target to treat dyslipidemia in last decade. Several genetic 
polymorphisms has been detected and characterised. PCSK9 gain-of-function (GOF) causes 
the severe hypercholesterolemia, while loss-of-functioned (LOF) mutations maintains low 
cholesterol profile and reduced risk of cardiovascular diseases. Discoveries of many GOF 
and LOF variants on PCSK9 gene were also found related to ethnicity. In Caucasian 
population, the R46L is known as one of the most potent LOF variant of PCSK9, lying at 
prodomain segment of PCSK9 protein, which reproducibly associated with significant 
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reductions in plasma levels of LDL-C (-15%) and reduction in CVD risk (-47%) by attenuating 
the autocatalytic cleavage of PCSK9 protein and hence reduction in plasma PCSK9 volume. 
The effect of PCSK9 mutations on plasma levels of LDL-C and coronary heart disease suggest 
that PCSK9 is a major determinant of plasma levels of LDL-C and hence an attractive target 
of cholesterol-lowering therapy. 
PCSK9 R46L has been identified in Whites subjects in a Dallas-Heart studies (DHS) 
with the penetration of about 3.2%, and reduces the plasma cholesterol levels (-15%)[6][5] 
[162]probably via its ability to reduces plasma PCSK9 levels (-22.30%)[6] and hence 
contribute in reduction in CVD risk too (-47%)[5].  
 
4.10. Genotype and allelic frequencies of PCSK9 rs11591147 (p.R46L) 
Table 1Error! Reference source not found. summarizes the genotype and allelic 
distribution of PCSK9 rs11591147 (c.5428 G>T; p.R46L), in the general population, the 
frequencies of the PCSK9 rs11591147 “G” variant allele and of the homozygous genotype 
(GG) is 98.90% and 97.81% respectively. In our population, we have not observed the 
homozygous genotype of recessive allele “TT” in our studied population. However, 
considering the 50% distribution and effect size over population, it comprises with about 
1.10% distribution in our PLIC cohort. 
Table 1. Genotype and allelic distribution of PCSK9 rs11591147(p.R46L) 
  GENOTYPES ALLELES 
 
PLIC 
subjects (n) 
GG (n; %) GT (n;%) G (%) T (%) 
Total 1919 1877; 97.81% 42; 2.19% 98.90 1.10 
Men 813 794; 42.30% 19; 41.87% 98.83 1.17 
Women 1106 1083;57.70% 23; 58.13% 98.96 1.04 
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4.11. General and clinical characteristics of PLIC subjects according to PCSK9 
rs11591147 (p.R46L). 
Table 2 summarizes general and clinical data of total population and subjects 
without hypolipidemics drugs. To observe the direct effect of R46L variant on plasma PCSK9 
levels, we only choose the subjects those were free of hypolipidemics drugs to avoid the 
confounding effects of drugs over plasma PCSK9 levels. 
In total population, the lipid phenotypes association with PCSK9 R46L genotypes 
appeared in various degree, where [values in Mean ± SEM] HDL (55.54 ± 0.33 vs 50.24 ± 
1.96; p=0.022), and ApoA1(149.35 ± 0.61 vs 139.88 ± 3.84; p=0.024) remained higher among 
R46R carriers than R46L carriers respectively, although, a trend for total cholesterol (9 
mg/dL difference) and LDL-c (10 mg/dL difference) were also appeared between the 
genotypes (R46R vs R46L) but it could not touch the statistical significance. However, when 
adjusted for age, gender and BMI, a significant trend appeared for LDL-c between the 
genotypes (p=0.007). 
On the other hand; the mean levels of BMI in carriers of R46L were higher than R46R 
(values in Mean ± SEM;  26.48 ± 0.09 vs 28.15 ± 0.61 respectively; p=0.011). In addition, 
R46L carriers were observed with higher in Triglycerides (108.60 ± 1.44 vs 137.17 ± 14.0; 
p=0.004), and glucose (92.83 ± 0.36 vs 100.0 ± 4.18; p=0.004) levels than for R46R- All values 
were in Mean ± SEM. 
Similarly, when subjects selected without hypolipidemics drugs, the 
pharmacogenomics effect on lipid phenotypes between carriers of R46R and R46L was 
neutral for HDL (58.37  ± 0.51 vs 48.82  ± 2.56; p=0.010 ), and ApoA1 (151.29  ± 0.87 vs 
134.29   ± 6.27; p=0.007) as observed in total population-[Table 2 A], however a statistical 
significance for total cholesterol (237.04  ± 1.34 vs 207.23  ± 10.32; p=0.002) and LDL-c 
(158.35  ± 1.26 vs 136.70  ± 8.93; p=0.017)  between the genotypes (R46R vs R46L) were 
appeared [Table 2 B]. This variation of association with total cholesterol and LDL levels 
prompted us to determine the plasma PCSK9 levels, as recent studies revealed the effect of 
R46L variants over PCSK9 secretion from hepatocytes. 
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Table 2. Anthropometric and clinical parameters according to PCSK9 rs11591147 (p.R46L) 
Table 2(A) Of total population 
 
 Age BMI TC LDLc HDLc TG Apo1 ApoB SBP DBP GLUCOSE 
R46R 
54.77 ± 
0.26 
26.48 ± 
0.09 
221.85 ± 
0.90 
144.58 ± 
0.83 
55.52 ± 
0.33 
108.60 ± 
1.44 
149.35 
±0.61 
113.61 
±0.60 
131.40 ± 0.40 
81.65 ± 
0.22 
92.83 ± 
0.362 
R46L 
54.17 ± 
1.69 
28.14 ± 
0.61 
212.10 ± 
6.62 
134.42 ± 
6.35 
50.24 ± 
1.96 
137.17 ± 
14.0 
139.88 ± 
3.84 
108.95 ± 
4.18 
134.39 ± 2.50 
83.54 ± 
1.37 
100.0 ± 4.18 
p-value 0.75 0.011 0.113 0.075 0.022 0.004 0.024 0.262 0.275 0.53 0.004 
Women 
R46R 
55.29 ± 
0.336 
26.04 ± 
0.14 
223.69 ± 
1.16 
144.48 ± 
1.09 
59.78 ± 
0.44 
97.34 ± 
1.52 
154.90 ± 
0.78 
112.61 
±0.76 
129.28 ±0.55 
80.42 ± 
0.29 
89.42 ± 0.37 
R46L 
54.18 ± 
2.39 
28.26 ± 
0.91 
224.18 ± 
9.52 
146.12 ± 
8.83 
51.95 ± 
2.54 
130.50 ± 
16.12 
144.95 ± 
5.92 
109.59 ± 
6.0 
134.77 ± 3.92 
84.32 ± 
2.31 
100.77 ± 
7.63 
p-value 0.62 0.049 0.54 0.54 0.01 0.002 0.034 0.32 0.23 0.43 0.03 
MEN 
R46R 
54.07 ± 
0.41 
27.07 ± 
0.122 
219.34 ± 
1.40 
144.76 ± 
1.30 
49.79 ± 
0.44 
123.90 ± 
2.61 
141.82 ± 
0.90 
114.96 ± 
0.97 
134.30 ± 0.58 
83.31 ± 
0.32 
97.45 ± 0.65 
R46L 
54.16 ± 
2.46 
28.01 ± 
0.83 
198.11 ± 
8.23 
120.86 ± 
8.32 
48.26 ±3.04 
144.89 ± 
24.15 
134.0 ± 
4.45 
108.21 ± 
5.93 
133.95 ± 3.02 
82.63 ± 
1.34 
99.11 ± 2.21 
p-value 0.53 0.053 0.72 0.04 0.18 0.002 0.074 0.05 0.43 0.37 0.05 
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2(b) Subjects free of hypolipidemics drugs 
 Age BMI TC LDLc HDLc TG Apo1 ApoB SBP DBP GLUCOSE PCSK9 
R46R 
60.47 ± 
0.37 
26.83  ± 
0.16 
237.04  ± 
1.34 
158.35  ± 
1.26 
58.37  ± 
0.51 
100.99  ± 
1.82 
151.29  ± 
0.87 
124.24  ± 
1.09 
131.22  ± 
0.59 
78.35  ± 
0.29 
98.89  ± 
0.53 
294.33  ± 
6.34 
R46L 
63.29  ± 
1.99 
28.84  ±  
0.78 
207.23  ± 
10.32 
136.70  ± 
8.93 
48.82  ± 
2.56 
108.52  ± 
10.24 
134.29  ± 
6.27 
100.29  ± 
6.36 
128.82  ± 
3.72 
76.17  ± 
1.51 
99.23  ± 
3.48 
136.97  ± 
23.10 
p-value 0.275 0.071 0.002 0.017 0.010 0.654 0.007 0.002 0.598 0.201 0.984 <0.001 
Women             
R46R 
60.66  ± 
0.54 
26.66  ± 
0.25 
240.48  ± 
2.01 
159.30  ± 
1.89 
62.14  ± 
0.79 
95.20  ± 
2.68 
157.36  ± 
1.22 
126.26  ± 
1.65 
128.69  ± 
0.94 
77.13  ± 
0.46 
95.84  ± 
0.72 
312.0  ± 
10.12 
R46L 
65.63  ± 
2.16 
28.92  ± 
1.30 
215.25  ± 
14.09 
142.87  ± 
13.48 
52.0  ± 
4.41 
101.75  ± 
12.78 
140.25  ± 
10.37 
107.75  ± 
8.06 
126.25  ± 
6.03 
73.75  ± 
2.63 
94.12  ± 
2.22 
132.98  ± 
33.68 
MEN             
R46R 
59.06  ± 
0.72 
27.07  ± 
0.20 
228.52  ± 
2.35 
153.64  ± 
2.25 
52.83  ± 
083 
108.23  ± 
3.47 
141.70  ± 
1.63 
118.66  ± 
1.80 
132.73  ± 
10.7 
79.37  ± 
0.49 
102.67 ± 
1.08 
276.90  ± 
10.91 
R46L 
57.33  ± 
3.91 
28.04  ± 
0.65 
205.50  
±19.87 
133.66  ± 
15.64 
49.16 ± 
3.10 
113.16  
±24.78 
137.66  ± 
8.49 
98.50  ± 
12.47 
130.83  ± 
5.83 
77.50  ± 
1.70 
98.83  ± 
3.11 
163.57  ± 
41.53 
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4.12. Common carotid intima-media thickness according to PCSK9 rs11591147 
(p.R46L genotype)- longitudinal study. 
The role of the increase in the common carotid artery (CCA) intima-media wall 
thickness (IMT) in the atherosclerotic plaque is still debatable. Similarly, plasma PCSK9 levels 
or local production of PCSK9 from vascular cells especially vascular smooth muscle cells 
(VSMCs) role in cIMT progression is not very well understood. We measured the intima-
media thickness of carotid artery of our all subjects enrolled in the PLIC study and also 
performed longitudinal study examining the predictive value of CCA-IMT measured at 
baseline and after 10 year follow ups. According to the PCSK9 R46L genotypes, the mean 
levels of cIMT at baseline (values in Mean ± SEM; 0.65 ± 0.003 vs 0.66 ± 0.017 mm; p= 0.142) 
and later 10 years follow ups (0.78 ± 0.005 vs 0.76 ± 0.23 mm; p= 0.116) did not reach to 
the statistical significance- [Table 3]. 
 
Table 3 :- PCSK9 R46L variants and status of intima-media thickness of carotid artery during 
follow up study 
 R46R [n; (mean ± SEM) R46L [n; (mean ± SEM) p- value 
Baseline 1848; (0.65 ± 0.003) 41; (0.66 ± 0.017) 0.142 
10 year later 1067; (0.78 ± 0.005) 25; ( 0.76 ± 0.23) 0.116 
 
4.13. PCSK9 R46L genotypes and plasma PCSK9 levels 
To evaluate the role of PCSK9 R46L variants with plasma PCSK9 levels, we first 
choose subjects those were free of lipid lowering drugs to avoid the confounding effect of 
drugs on plasma PCSK9 levels. Some drugs especially statins, elevates the PCSK9 expression, 
as reported in many studies. As expected, we have observed a difference of about 157.36 
ng/ml (about 53.46% difference) of mean levels in plasma PCSK9 between R46L genotypes, 
where the mean levels of plasma PCSK9 in R46R carrier was about 294.33 ± 6.34 ng/ml while 
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it was 136.97 ± 23.10 ng/ml in R46L carriers (values in Mean ±  SEM). The reduction in 
plasma PCSK9 levels for R46L genotypes was irrespective to gender. Men of R46L carrier had 
about 40.93% reduction in mean plasma PCSK9 levels than men R46R carrier (163.57 ± 41.53 
vs 276.90 ± 10.91 respectively; p <0.05), similarly, but highest reduction in plasma PCSK9 
levels of about 57.38% (mean value) was seen in case of women carrying heterozygous R46L 
than women of R46R carrier- [Table 4]. 
 
Table 4. Difference of plasma PCSK9 levels and associated reduction in LDL and total cholesterol as per the 
PCSK9 R46L genotypes. 
 
 R46R R46L p 
% Reduction 
in PCSK9 
% Reduction in 
LDL [refer table1] 
% Reduction in 
Total cholesterol 
[refer table1] 
All 294.33 ± 6.34 136.97 ± 23.10 <0.001 53.46 % 13.49% 12.39% 
Men 276.90 ± 10.91 163.57 ± 41.53 <0.002 40.93 % 13.0% 10.07% 
Women 312.00 ± 10.12 132.98 ± 33.68 <0.001 57.38% 10.31% 10.49% 
 
4.14. Plasma PCSK9 levels in total PLIC cohort 
Plasma PCSK9 levels were determined for all PLIC subjects of visit 3 (n= 1517) 
attending at Bassini hospital, Milan, Italy. All general and biochemical analysis were 
performed for the study and recorded for Age, BMI, lipid profiles, blood pressure, PCSK9 
level, CRP and cIMT progression- can be seen in Table 5. 
Plasma PCSK9 levels were determined for all 1517 subjects and correlation studies 
were performed, we excluded the subjects those were under lipid lowering drugs (like 
Statins, fibrates etc) to avoid the confounding effect over plasma PCSK9 levels. Thereby the 
final selected 1110 subjects were studied (free of lipid lowering drugs), At prima facie, the 
distribution of plasma PCSK9 levels (Mean ± SD) were not distributed normally among the 
population, where the mean plasma PCSK9 levels in total 1110 subjects was 285 ± 173.7 
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ng/ml (range 8.18 ng/ml to 1432.20 ng/ml) and was found increased in women than their 
age-matched man ( mean ± SD; 296.35 ± 176.52 vs 267.84 ±168 ng/ml respectively; p=0.008) 
- [Table 5] [Figure 28 A-D] and was highest in post-menopausal women (n=618)  than pre-
menopausal(n=63)  (Mean ± SD; 332.69 ±  207.08  vs 259.36  ± 152.11 ng/ml; p= 0.007)-
[Figure 28- E]. When stratified for hormone replacement therapy (HRT) vs non-hormone 
replacement therapy (non-HRT) effect over plasma PCSK9 levels among post-menopausal 
women, no dose effect of HRT on plasma PCSK9 levels were observed among HRT-taker 
versus non-HRT-takers (p=0.480)-[Figure 28-F] . 
 
Figure 28. Plasma PCSK9 levels in PLIC cohort 
A)Plasma PCSK9 levels in the entire studied cohort (n= 1.110); B) Plasma PCSK9 levels in the women  
cohort (n= 681); C) Plasma PCSK9 levels in the men cohort (n= 429); D) gender difference in plasma  
PCSK9 levels. E) difference in plasma PCSK9 levels according to menopausal status. E) difference in  
plasma PCSK9 levels according to use of hormone replacement therapy (HRT). P is derived from  
Analysis of Co-Variances (ANCOVA) using an age-adjusted model. 
 
 
Results 
72 
 
The another difference in plasma PCSK9 levels were observed between lipid 
lowering treatment vs non-lipid lowering treatment thus was the main excluding criteria for 
our further analysis. Statins treated subjects (n-337) had about 36% high plasma PCSK9 
levels than subjects free of hypolipidemics drugs (p<0.001)- [Figure 29].  
 
 
 
Figure 29. Statin induces plasma PCSK9 levels:-  
Statins treated subjects had about 36% higher plasma PCSK9 levels than non-treated subjects in our  
studied cohort. 
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4.15. Clinical and Anthropometric parameters according to PCSK9 levels  
We further performed Univariate analysis to evaluate high order interaction 
between plasma PCSK9 levels of PLIC cohort and clinical and general variables. As stated in 
Table 6 plasma PCSK9 levels were found associated with various metabolic parameters viz 
BMI (r=0.075, p= 0.024), LDL-c (r=0.094; p=0.002), ApoB (r=0.152, p<0.001); Total 
cholesterol (r=0.151, p<0.001); HDL (r=0.124, p<0.001) triglycerides (r=0.114, p<0.001) and 
ApoA1 (r=0.128, p<0.001), although all associated parameter with PCSK9 levels was not 
Table 5. General characteristics and plasma lipid levels of PLIC subjects 
 
 
All (n= 1110) 
Mean±S.D 
Men (n= 429; 
38.60%) 
Mean±S.D 
Women (n=681; 
61.40%) 
Mean±S.D 
P value (Men vs 
Women) 
Age (years) 59.6 ± 11.5 59.9 ± 1.5 59.4 ± 11.5 0.491 
BMI (kg/m²) 26.7 ± 4.2 27.1 ± 3.4 26.4 ± 4.7 0.013 
Waist (cm) 90.99 ± 11.8 97.6 ± 9.1 86.8 ± 11.5 <0.001 
Total Cholesterol (mg/dL) 234.61 ± 42.14 226.9 ± 43.37 239.47 ± 40.63 <0.001 
LDL-C (mg/dL) 156.18 ± 38.89 153.05 ± 40.46 158.15 ± 37.78 0.034 
HDL-C (mg/dL) 58.52 ± 14.89 52.55 ± 13.0 62.28 ± 14.78 <0.001 
Triglycerides(mg/dL) 99.84 ± 54.69 107.24 ± 58.46 95.19 ± 51.68 <0.001 
Fasting glucose (mg/dL) 98.85 ± 15.94 103.38 ± 17.12 96.0 ± 14.45 <0.001 
SBP (mmHg) 130.0 ± 18 133.0 ± 17.43 128.0 ± 18 <0.001 
DBP (mmHg) 78.0 ± 9 79.0 ± 8 77.0 ± 9 <0.001 
ApoAI(mg/mL) 151.44 ± 29.30 141.12 ± 25.45 157.93 ± 22.96 <0.001 
ApoB (mg/mL) 123.01 ± 33.09 117.76 ± 32.44 126.31 ± 33.10 <0.001 
CRP(mg/L) 2.82 ± 3.17 2.64 ± 3.25 2.93 ± 3.11 0.146 
cIMT (mm) 0.74 ± 0.13 0.75 ± 0.13 0.73 ± 0.13 0.003 
PCSK9 (ng/mL) 285.3 ± 173.7 267.84 ± 168.0 296.35 ± 176.52 0.008 
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more than 16% in a spearmen coefficient correlation analysis- [Table 6]. To know whether 
this degree of variability or association with metabolic parameters also exist between sexes-
as PCSK9 expression also varies due to gender. We found that despite of higher PCSK9 in 
women plasma, Men cohort had presented modest association between plasma PCSK9 
levels and metabolic determinants than women. The reason of this low association in 
women despite of higher in plasma PCSK9 levels is not fully understood, but hormonal 
intervention might be one of the primary reason. 
Table 6. Clinical and Anthropometric parameters according to plasma PCSK9 levels 
 All Men Women 
 
 
p 
 
p 
 
p 
Age (years) -0.019 0.520 -0.061 0.205 0.015 0.687 
BMI (kg/m²) 0.075 0.024 0.088 0.097 0.080 0.060 
Waist (cm) 0.056 0.070 0.086 0.084 0.106 0.007 
Total Chol (mg/dL) 0.151 <0.001 0.196 <0.001 0.105 0.006 
LDL-c (mg/dL) 0.094 0.002 0.126 0.009 0.064 0.098 
HDL (mg/dL) 0.124 <0.001 0.161 <0.001 0.061 0.112 
Triglycerides(mg/dL) 0.114 <0.001 0.146 0.002 0.113 0.003 
Fasting Glucose (mg/dL) 0.019 0.524 0.106 0.028 0.008 0.844 
SBP (mmHg) 0.005 0.870 -0.001 0.986 0.024 0.527 
DBP (mmHg) 0.037 0.217 0.053 0.273 0.040 0.294 
ApoAI (mg/mL) 0.128 <0.001 0.166 0.001 0.062 0.106 
ApoB (mg/mL) 0.152 <0.001 0.181 <0.001 0.120 0.002 
CRP (mg/L) 0.031 0.308 0.019 0.703 0.030 0.438 
cIMT (mm) 0.010 0.747 0.002 0.967 0.028 0.47 
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4.16. Increased levels of Plasma PCSK9 levels observed in Men with Metabolic 
syndrome phenotypes  
Since most of the association between plasma PCSK9 levels and clinical variables 
were modestly stronger in men than women cohort, we further aim to understand the role 
or levels of plasma PCSK9 in metabolic syndrome (MetS) phenotypes, which is a common 
cluster of multiple risk factors (like dyslipidemia, hypertension and hyperglycemia) of CVDs, 
as defined by ATP-III guidelines.  
At prima facie, the PCSK9 levels were found higher in MetS cohort , therefore, we 
also looked for genderwise difference in plasma PCSK9 levels in subjects with MetS 
phenotype, Men (n=134) and women (n=193) of MetS group compared with non-MetS of 
men (n=295) and women (n=488) for plasma PCSK9 levels distribution-[Table 7] [Figure 30].  
A difference in mean plasma levels of about 31ng/ml (or increased by 10.47%) was existed 
between men of MetS and men of non-MetS phenotypes with statistical significant p-value 
of 0.04. While difference in plasma PCSK9 levels between MetS and non-MetS cohort of 
women did not reach to the statistical significance (p= 0.252). 
Table 7. Plasma PCSK9 levels in subjects with Metabolic syndrome vs non-Metabolic syndrome 
 Plasma PCSK9 ( mean ± S.D   ng/ml) 
 All (n;  mean ± S.D) Men (n;  mean ± S.D) Women (n; mean ± S.D) P Value 
MS Group 327; 301.04 ± 187.54 134;   288.63 ± 167.95 193;   309.66  ± 200 0.319 
Non-MS Group 783; 278.77 ± 167.37 295;   258.40  ± 167.51 488;   291.08  ± 166.25 0.008 
P value 0.016 0.04 0.236  
Our data suggest that despite of high in plasma PCSK9 levels, women generally 
present protection against various metabolic disturbances during their pre-menopausal 
status- as stated in various other studies. We further try to understand the robustness of 
increased plasma PCSK9 levels in MetS, we choose to perform longitudinal analysis on the 
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subjects those had increased plasma PCSK9 levels but did not have MetS phenotype at 
baseline. 
 
 
Figure 30. Plasma PCSK9 levels in Metabolic syndrome in Total population and  
genderwise manner. 
(A) Plasma PCSK9 levels in total population of MetS Vs Non MetS group (B) Plasma PCSK9 levels  
difference in Men Vs Men in MetS and non MetS group (C) Plasma PCSK9 levels difference in Women 
Vs Women in MetS and Non MetS group 
 
4.17. PCSK9 levels are independent prognostic marker of Metabolic Syndrome  
To determine whether to consider plasma PCSK9 levels as independent prognostic 
marker of MetS incidence. Subjects with high plasma PCSK9 levels (>Mean levels) but free 
of MetS phenotypes were followed for 4 years, 1.6% subjects of studied group had 
developed MetS during a median of 4 years of follow up time. Cox regression model, 
adjusting for age, gender, lifestyle habits and ongoing treatments, showed that high plasma 
PCSK9 levels  were predictive of an increased risk of MetS in men (HR= 1.616 [1.112-1.918] 
HR 95% C.I., P= 0.043), but not in women (HR= 1.007 [0.987-1.617] HR 95% C.I., P= 0.515). 
Our data suggest that PCSK9 levels might be considered as a gender-specific prognostic 
marker for the incidences of MetS in a longer run.   
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SECTION [B2]. GPER P.P16L GENOTYPES AND ROLE IN LIPID HOMEOSTASIS AND ATHEROSCLEROSIS 
PROGRESSION 
We next investigated the role of GPER rs11544331 variants in lipid metabolism and 
peripheral atherosclerosis progression in our PLIC cohort. The reason of choosing this 
variant for the study, is due to the mounting hypothesis of estrogen mediated regulation of 
PCSK9 expression, GPER rs11544331 (p.P16L) variants were recently reported to be 
associated with sex-specific increase in blood pressure and cholesterol levels in women, 
further, analysis on HepG2 cells also revealed that GPER activity downregulates PCSK9 
expression and thus enhances the expression of LDLRs and increased LDL uptake.  
These findings prompted us to evaluate this GPER rs11544331 SNP in our 
population, as we have already studied the plasma PCSK9 levels difference in women and 
men, however, we were also interested to know the molecular mechanism behind the 
cause. 
 
4.18. Genotype and allelic distribution frequency of GPER rs11544331 genotypes  
The genotype distribution of the GPER rs11544331 polymorphism was within Hardy-
Weinberg equilibrium. To understand better association of GPER rs11544331 variants role, 
we have done group-wise stratification, Group-I was consist of total population (n-= 1405) 
and Group-II was consist of subjects free of hypolipidemics drugs (n=898) to avoid the lipid 
lowering drugs effect over plasma PCSK9 levels.  
The frequencies of the GPER rs11544331 ‘C’ variant allele and of the homozygous 
genotype (CC) was higher in total population (Group-I) of 1405 subjects (69.68 % and 47.97% 
respectively) in comparison to the ‘T’ variant allele and of the homozygous genotype (TT) 
(30.32%, 8.61% respectively). Further, no significant differences in TT-genotype 
distributions between men and women (8.87 % vs 8.44% respectively) were observed –
[Table 8]. A similar trend were observed in subjects without lipid lowering drugs(n=898; 
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Group-II), where, ‘C’ variant allele and of the homozygous genotype (CC) was higher in total 
population (70.38 % and 49.44% respectively) in comparison to the ‘T’ variant allele and of 
the homozygous genotype (TT) (29.62%, 8.69% respectively). And, no significant differences 
in TT-genotype distribution was observed among men and women (8.48 % vs 8.83% 
respectively). 
Table 8. Penetration of Genotype [n (%)] and allelic frequency of the rs11544331 variants of GPER gene 
in Italian general population. 
  GENOTYPE ALLELES 
 PLIC  subjects CC (n; %) CT (n; %) TT (n; %) C (%) T (%) 
GROUP-I 1405 674; (47.97%) 610 (43.42%) 121 (8.61%) 69.68% 30.32% 
MEN 575 276; (48%) 248 (43.13%) 51 (8.87%) 69.57% 30.43% 
WOMEN 830 398; (47.95%) 362 (43.61%) 70 (8.44%) 69.76% 30.24% 
χ² 0.093  
p-value 0.954  
GROUP-II 898 444; (49.44%) 376; (41.87%) 78; (8.69%) 632; 70.38% 266; 29.62% 
MEN 354 182; (51.41%) 142; (40.11 %) 30; (8.48%) 253; 71.47% 101; 28.53% 
WOMEN 544 262; (48.16%) 234; (43.01%) 48; (8.83%) 379; 69.67% 165; 30.33% 
χ² 0.92  
p-value 0.63  
 
4.19. General and biochemical characteristics of PLIC subjects according to GPER 
rs11544331 gene variants. 
We studied GPER variants role in total cohort (n=1405, henceforth called Group- I) 
[Table 9] and in subjects free of lipid lowering drugs (n=898; henceforth called Group- II) 
[Table 10].  
Univariate analysis were performed in both the studied groups to evaluate high 
order interaction among GPER genotypes with general and biochemical profiles. No 
significant association were found among carriers of different GPER genotypes in either of 
the studied group (Group-I & II) for anthropometric and clinical parameters such as BMI, 
Waist, LDL, TC, Tg, HDL, Glucose, SBP, DBP etc. in either of the groups [Table 9 & Table 10]. 
Previous studies on the role of GPER P16L genotype on total cholesterol by Hussain et al and 
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on blood pressure by Feldman et al was reported as sex-specific activity of GPER, where only 
women was affected due to the non-synonymous change(rs11544331; C>T; 16L) in GPER 
gene. We also did gender-wise stratification in both the groups to evaluate the sex-specific 
role of GPER P16L genotype and their influence on lipids and blood pressures. No significant 
association of 16L genotype with total cholesterol were seen among sexes (men vs Women; 
Mean ± SEM [mg/dL]) in group-I (216.86. ± 5.0 vs 231.59 ± 4.10; p>0.05)-[Table 11], and in 
group II (218.63 ± 5.95 vs 243.29 ± 6.02; p>0.05)-[Table 12]. Similarly, no association was 
there for blood pressure among GPER 16L genotype and sexes of either group (men vs 
Women; Mean ± SEM [mg/dL]) in group-I (134.12. ± 2.35 vs 133.29 ± 2.4; p>0.005)-[Table 
11], and in group II (132.83 ± 2.84 vs 131.77 ± 3.20; p>0.005) -[Table 12] 
Table 9. General and clinical characteristics of the GROUP-I cohort according to the rs11544331 SNP of GPER gene. 
 Total (n= 1405) CC (n=674) CT (n=610) TT (121) p value CC Vs CT CC vs TT CT VS TT 
Age 54.90 ± 0.29 54.81 ± 0.43 54.96 ± 0.45 55.10 ± 0.99 0.952 0.811 0.795 0.902 
BMI (Kg/m²) 26.56 ± 0.11 26.69 ± 0.17 26.37 ± 0.17 26.82 ± 0.33 0.326 0.186 0.749 0.290 
Waist 90.26 ± 0.35 90.50 ± 0.48 89.77 ± 0.56 91.38 ± 1.0 0.377 0.318 0.498 0.219 
Tg (mg/dL) 108.59 ± 1.71 108.01 ± 2.3 108.33 ± 2.6 113.12 ± 6.3 0.716 0.929 0.420 0.453 
TC (mg/dL) 221.69 ± 1.0 220.15 ± 1.48 222.66 ± 1.55 225.38 ± 3.2 0.271 0.240 0.166 0.474 
LDL (mg/dL) 145.24 ± 0.95 144.66 ± 1.37 145.29 ± 1.46 148.18 ± 3.11 0.608 0.751 0.319 0.418 
HDL (mg/dL) 54.73 ± 0.38 53.88 ± 0.54 55.69 ± 0.59 54.57 ± 1.34 0.079 0.025 0.628 0.434 
ApoA1 (mg/dL) 146.96 ± 0.68 145.78 ± 0.99 148.24 ± 1.0 147.04 ± 2.5 0.235 0.089 0.622 0.641 
ApoB (mg/dL) 113.19 ± 0.68 112.97 ± 0.97 112.83 ± 1.0 116.25 ± 2.22 0.389 0.919 0.196 0.181 
Glycemia (mg/dL) 91.15 ± 0.43 90.08 ± 0.49 92.06 ± 0.79 92.51 ± 1.3 0.060 0.030 0.131 0.780 
SBP (mmHg) 132.94 ± 0.45 132.79 ± 0.64 132.96 ± 0.68 133.64 ± 1.7 0.878 0.856 0.612 0.689 
DBP (mmHg) 82.96 ± 0.24 83.09 ± 0.33 82.65 ± 0.37 83.88 ± 0.83 0.345 0.385 0.370 0.168 
Non-HDL (mg/dL) 166.96 ± 1.05 166.26 ± 1.52 166.96 ± 1.61 170.80 ± 3.31 0.507 0.752 0.244 0.328 
Remnants (mg/dL) 21.71 ± 0.34 21.60 ± 0.47 21.66 ± 0.52 22.62 ± 1.27 0.716 0.929 0.420 0.453 
Note:- Values are indicated in Mean ± SEM, and p-value considered significant if less than 0.05. 
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Note:- Values are indicated in Mean ± SEM, and p-value considered significant if less than 0.05. 
 
 
 
 
 
 
Table 10. General and clinical characteristics of the PLIC cohort (Group-II) according to the rs11544331 SNP of GPER 
gene 
 Total (n= 898) CC (n=444) CT (n=376) TT (78) p value CC Vs CT CC vs TT CT VS TT 
Age 60.07 ± 0.37 59.94 ± 0.53 60.30 ± 0.57 59.68 ± 1.23 0.854 0.646 0.848 0.655 
BMI (Kg/m²) 26.83 ± 0.15 26.95 ± 0.21 26.64 ± 0.25 27.02 ± 0.49 0.599 0.346 0.911 0.524 
Waist 91.52 ± 0.39 92.42 ± 0.53 90.30 ± 0.64 91.73 ± 1.36 0.051 0.015 0.631 0.367 
Tg (mg/dL) 100.76 ± 1.85 103.02 ± 2.71 98.13 ± 2.76 100.52 ± 6.46 0.457 0.211 0.715 0.73 
TC (mg/dL) 233.92 ± 1.30 231.86 ± 1.95 236.39± 1.86 233.80 ± 4.54 0.254 0.098 0.685 0.595 
LDL(mg/dL) 155.62 ± 1.21 154.68 ± 1.81 156.59± 1.76 156.35 ± 4.19 0.743 0.454 0.708 0.958 
HDL (mg/dL) 58.22 ± 0.49 56.57 ± 0.66 60.37 ± 0.81 57.34 ± 1.64 0.001 0.001 0.672 0.101 
ApoAI (mg/dL) 151 ± 0.84 148.65 ± 1.16 154.19± 1.33 149.12 ± 2.91 0.006 0.002 0.877 0.106 
ApoB (mg/dL) 122.27 ± 1.03 121.51 ± 1.52 123.41± 1.52 121.14 ± 3.57 0.646 0.383 0.922 0.557 
Glycemia 
(mg/dL) 
98.63 ± 0.51 97.88 ± 0.68 99.31 ± 0.83 99.65 ± 1.96 0.352 0.19 0.353 0.86 
SBP (mmHg) 130.51 ± 0.61 130.54 ± 0.91 130.12± 0.90 132.18 ± 2.24 0.67 0.746 0.472 0.372 
DBP (mmHg) 78.15 ± 0.29 78.25 ± 0.42 78.19 ± 0.44 77.37 ± 1.15 0.716 0.919 0.419 0.459 
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Table 11. Sex-specific impact of rs11544331 variants of GPER gene on general and biochemical parameters of Group-I. 
 
 
Total ; 
% 
Age BMI Waist Tg TC LDL HDL ApoAI ApoB GLYCEMIA SBP DBP 
Non-
HDL 
Remnants 
In Men 
575;   
40.8% 
54.60 
± 0.46 
27.06 
± 0.14 
96.31 ± 
0.40 
123.56 
± 3.14 
218.67 
± 1.59 
145.35 
± 1.49 
48.60 
± 0.49 
137.49 
± 0.96 
114.91 
± 1.0 
95.38 ± 
0.69 
135.69 
± 0.66 
84.50 
± 0.36 
170.06 
± 1.62 
24.71 ± 
0.62 
CC 
276; 
48.00% 
54.47 
± 0.67 
26.99 
± 0.21 
96.13 ± 
0.58 
120.37 
± 4.27 
216.50 
± 2.18 
143.95 
± 2.06 
48.47 
± 0.67 
137.02 
± 1.38 
113.72 
± 1.46 
93.74 ± 
0.83 
135.60 
± 0.97 
84.64 
± 0.50 
168.03 
± 2.25 
24.07 ± 
0.85 
CT 
248; 
43.14% 
54.87 
± 0.70 
27.0 ± 
0.21 
96.57 ± 
0.63 
125.80 
± 5.01 
221.45 
± 2.5 
147.26 
± 2.3 
49.02 
± 0.74 
138.54 
± 1.42 
116.06 
± 1.78 
97.25 ± 
1.21 
136.11 
± 1.0 
84.58 
± 0.58 
172.42 
± 2.61 
25.16 ± 1.0 
TT 
51; 
8.86% 
54.04 
± 1.61 
27.38 
± 0.37 
96.11 ± 
1.10 
129.92 
± 11.3 
216.86 
± 5.0 
143.58 
± 4.80 
47.29 
± 2.0 
134.90 
± 3.82 
115.76 
± 3.64 
95.24 ± 2.3 
134.12 
± 2.35 
83.43 
± 1.21 
169.56 
± 4.80 
25.98 ± 
2.27 
p value  0.858 0.763 0.862 0.585 0.316 0.537 0.613 0.534 0.577 0.054 0.715 0.657 0.433 0.585 
CC VS 
CT 
 0.686 0.80 0.60 0.41 0.14 0.29 0.59 0.45 0.30 0.01 0.71 0.93 0.19 0.41 
CC vs TT  0.80 0.46 0.98 0.40 0.95 0.94 0.51 0.54 0.60 0.55 0.54 0.36 0.79 0.40 
CT vs TT  0.63 0.55 0.74 0.72 0.43 0.50 0.34 0.30 0.94 0.43 0.41 0.39 0.63 0.72 
In 
Women 
830; 
59.07% 
55.11 
± 0.38 
26.22 
± 0.16 
86.26 ± 
0.45 
98.22 ± 
1.82 
223.78 
± 1.32 
145.16 
± 1.24 
58.97 
± 0.50 
153.52 
± 0.88 
112.00 
± 0.87 
88.22 ± 
0.53 
131.02 
± 0.60 
82.01 
± 0.44 
164.81 
± 1.38 
19.64 ± 
0.36 
CC 
398; 
47.95% 
55.05 
±0.55 
26.48 
± 0.24 
86.79 ± 
0.62 
99.44 ± 
2.68 
222.67 
± 2.0 
145.15 
± 1.83 
57.63 
± 0.74 
151.86 
± 1.29 
112.46 
± 1.30 
87.55 ± 
0.56 
130.82 
± 0.84 
81.32 
± 0.47 
165.04 
± 2.05 
19.88 ± 
0.53 
CT 
362; 
43.62% 
55.03 
± 0.59 
25.89 
± 0.25 
85.43 ± 
0.73 
96.36 ± 
2.65 
223.48 
± 1.92 
143.95 
± 1.83 
60.26 
± 0.77 
154.89 
± 1.33 
110.62 
± 1.29 
88.50 ± 1.0 
130.79 
± 0.91 
84.21 
± 1.14 
163.22 
± 2.02 
19.27 ± 
0.53 
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TT 
48; 
8.43% 
55.87 
± 1.24 
26.43 
± 0.49 
87.56 ± 
1.58 
100.89 
± 6.92 
231.59 
± 4.10 
151.53 
± 4.08 
59.87 
± 1.46 
155.89 
± 2.91 
116.60 
± 2.79 
90.53 ± 
1.67 
133.29 
± 2.4 
81.89 
± 0.31 
171.71 
± 4.55 
20.17 ± 
1.38 
p value  0.83 0.22 0.25 0.65 0.19 0.26 0.04 0.19 0.17 0.29 0.52 0.046 0.26 0.65 
CC VS 
CT 
 0.97 0.09 0.15 0.420 0.77 0.64 0.013 0.103 0.316 0.396 0.97 0.29 0.530 0.420 
CC vs TT  0.57 0.93 0.66 0.832 0.07 0.16 0.235 0.225 0.206 0.136 0.274 0.059 0.196 0.832 
CT vs TT  0.56 0.39 0.23 0.510 0.10 0.10 0.838 0.765 0.070 0.314 0.271 0.014 0.102 0.510 
Note:- Values are indicated in Mean ± SEM, and p-value considered significant if less than 0.05. 
 
Table 12. Sex-specific impact of rs11544331 variants of GPER gene on general and biochemical parameters (Group-II). 
 Total; % Age BMI Waist Tg TC LDL HDL ApoAI ApoB 
Glycemi
a 
SBP DBP PCSK9 
 
In Men 
354; 
39.42% 
59.80 ± 
0.59 
27.07 ± 
0.18 
97.50 ± 
0.46 
108.20 ± 
3.13 
226.67 ± 
1.98 
152.67 ± 
1.84 
52.54 ± 
0.66 
141.57 
±1.32 
117.59 ± 
1.53 
102.42 ± 
0.88 
132.68 ± 
0.93 
79.25 ± 
0.43 
269.49 ± 
9.30 
CC 
182; 
51.41% 
59.47 ± 
0.82 
27.05 ± 
0.24 
97.67 ± 
0.62 
108.77 ± 
4.38 
224.91 ± 
2.94 
151.63 ± 
2.72 
51.52 ± 
0.86 
140.26 ± 
1.78 
116.92 ± 
2.30 
100.47 ± 
0.99 
132.80 ± 
1.44 
79.53 ± 
0.62 
258.42 ± 
12.56 
CT 
142; 
40.12% 
60.44 ± 
0.92 
26.96 ± 
0.32 
97.08 ± 
0.78 
106.53± 
4.63 
230.6 ± 
2.92 
155.55± 
2.69 
54.24 ± 
1.18 
143.75± 
2.20 
119.88± 
2.30 
105.19± 
1.70 
132.50± 
1.31 
78.98 ± 
0.67 
287.39 ± 
14.99 
TT 
30; 
8.47% 
58.77 ± 
2.22 
27.68 ± 
0.66 
98.50 ± 
1.45 
112.60 ± 
13.7 
218.63 ± 
5.95 
145.41 ± 
6.21 
50.70 ± 
1.79 
139.16 ± 
4.16 
110.80 ± 
3.82 
101.13 ± 
2.45 
132.83 ± 
2.84 
78.82 ± 
1.26 
254.09 ± 
35.12 
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p value  0.645 0.609 0.674 0.863 0.185 0.296 0.11 0.394 0.269 0.036 0.987 0.797 0.298 
CC VS 
CT 
 0.439 0.810 0.545 0.735 0.173 0.315 0.054 0.212 0.363 0.011 0.879 0.544 0.141 
CC vs TT  0.751 0.379 0.633 0.743 0.393 0.364 0.737 0.822 0.283 0.839 0.993 0.663 0.901 
CT vs TT  0.458 0.321 0.421 0.610 0.110 0.147 0.160 0.359 0.119 0.221 0.925 0.929 0.351 
In 
Women 
 
60.25 ± 
0.47 
26.67 ± 
0.22 
87.61 ± 
0.51 
95.91 ± 
2.26 
238.65 ± 
1.69 
157.54 ± 
1.60 
61.92 ± 
0.65 
157.14 ± 
1.01 
125.32± 
1.37 
96.17 ± 
0.60 
129.09 ± 
0.81 
77.44 ± 
0.39 
307.51 ± 
8.51 
CC 
262; 
48.16% 
60.27 ± 
0.69 
26.88 ± 
0.33 
88.78 ± 
0.71 
99.02 ± 
3.43 
236.68± 
2.56 
156.79± 
2.41 
60.08 ± 
0.89 
154.47± 
1.42 
124.69± 
2.01 
96.09 ± 
0.92 
128.97±
1.16 
77.37± 
0.56 
291.25 ± 
11.90 
CT 
234; 
43.02% 
60.22 ± 
0.73 
26.45 ± 
0.35 
86.31 ± 
0.81 
93.01 ± 
3.39 
239.90± 
2.38 
157.22± 
2.31 
64.08 ± 
1.02 
160.51± 
1.53 
125.57± 
2.01 
95.72 ± 
0.76 
128.68 ± 
1.20 
77.71 ± 
0.57 
313.27 ± 
13.65 
TT 
48; 
8.82% 
60.25 ± 
1.44 
26.61 ± 
0.69 
87.50 ± 
1.77 
92.97 ± 
5.91 
243.29± 
6.02 
163.19± 
5.42 
61.50 ± 
2.23 
155.35± 
3.70 
127.60± 
5.10 
98.72 ± 
2.80 
131.77± 
3.20 
76.46 ± 
1.69 
366.92± 
24.13 
p value  0.99 0.66 0.73 0.42 0.46 0.54 0.013 0.015 0.837 0.408 0.583 0.686 0.043 
CC VS 
CT 
 0.958 0.371 0.022 0.207 0.364 0.899 0.003 0.005 0.763 0.774 0.863 0.678 0.217 
CC vs TT  0.990 0.751 0.495 0.467 0.286 0.276 0.550 0.812 0.564 0.237 0.348 0.534 0.015 
CT vs TT  0.986 0.847 0.531 0.997 0.588 0.314 0.281 0.167 0.689 0.182 0.304 0.394 0.086 
Note:- Values are indicated in Mean ± SEM, and p-value considered significant if less than 0.05.        
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4.20. GPER rs11544331 variants influences plasma PCSK9 levels in a sex-specific 
manner 
We chose to perform correlation studies among the different carriers of GPER 
genotypes and plasma PCSK9 levels only in the Group-II subjects (n=898; free of 
hypolipidemics), to avoid the confounding effect of hypolipidemic drugs over plasma PCSK9 
levels, as reported in various clinical based studies. In general, no significant association 
between clinical variables (nearly all) and rs11544331 genetic variants of GPER gene in a 
univariate analysis were observed- [Table 10]. However, a modest association were found 
among carriers of GPER genotypes (CC, CT and TT) and plasma PCSK9 in total group-II cohort; 
[277.49 ± 8.71; 303.52 ± 10.22 and 324.34 ± 20.95 respectively; p=0.045]- [Table 13 and 
Figure 31A], which were only remained significant with women cohort (n=544) (291.25 ± 
11.90; 313.27 ± 13.65; 366.92 ± 24.13; p=0.043)- [Table 14 and Figure 31 B]. The mean 
values of plasma PCSK9 levels (mean ± SEM; ng/ml) in total cohort of group-II was 292. ± 
6.35 ng/ml, and was higher in women (307.51 ± 8.51 ng/ml) than men (269.29 ± 9.30 ng/ml), 
was further higher with TT carriers (p.P16L) of women than men of the same genotype 
(366.92 ± 24.13 and 254.09 ± 35.12 respectively; p=0.029)-[Figure 31 C]. However, the 
genotype frequency for P16L variants was insignificantly different among men and women 
(8.48% vs 8.83% respectively; p>0.05). 
We further investigated the possibility of GPER gene rs11544331variants (p.P16L) 
induced plasma PCSK9 levels effect on lipid levels and other clinical parameters in women 
of TT carriers (n=48). However, we failed to see the direct effect of increased plasma PCSK9 
association with either of any biochemical parameters (data not shown). 
Table 13. Plasma PCSK9 levels (ng/mL) in total population of Group-II 
GROUP-II 
Total (n= 
898) 
CC (n=444) CT (n=376) TT (78) p value CC Vs CT CC vs TT CT VS TT 
PCSK9 
LEVELS 
292.39 ± 6.35 277.49± 8.71 
303.52± 
10.22 
324.34± 
20.95 
0.045 0.051 0.045 0.38 
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Table 14. Genderwise plasma PCSK9 distribution (ng/mL) among GPER genotypes of Group-II 
GROUP-II 
ALL 
(n=898) 
CC CT TT P 
CC Vs 
CT 
CC vs 
TT 
CT VS 
TT 
MEN 
269.49 ± 
9.30 
258.42 ± 
12.56 
287.39 ± 
14.99 
254.09 ± 
35.12 
0.298 0.141 0.901 0.351 
WOMEN 
307.51 ± 
8.51 
291.25 ± 
11.90 
313.27 ± 
13.65 
366.92 ± 
24.13 
0.043 0.217 0.015 0.086 
 
 
 
 
 
 
 
 
 
 
Figure 31. Plasma PCSK9 distribution in PLIC cohort according to rs11544331 variants  
of GPER gene. 
 
Panel (a) Mean values of circulating plasma PCSK9 levels in total population according to genotypes 
of rs11544331 variants of GPER gene, carriers of TT-genotypes (p.P16L) had higher circulating plasma 
PCSK9 levels than their counterparts. Panel (b) Representing the circulatory plasma PCSK9 levels 
difference between sexes, women carriers presenting higher plasma PCSK9 levels than men in our 
studied cohort. Panel (c) A difference of mean values of plasma PCSK9 levels between TT-carriers of 
men and women, where women had about 112.83ng/ml high plasma PCSK9 levels than men of similar 
genotype (L16) 
All values are in Mean ± SEM 
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4.21. Carotid atherosclerosis progression is not associated with GPER rs11544331 
SNP 
We further evaluated the GPER variants (rs11544331) role in the progression of 
carotid atherosclerosis, and to the best of our knowledge, this is the first evaluation 
performed in relation to GPER activity in Italian general population. GPER P16L genotypes 
in total population of Group I and II, and Women cohort of group I and II were chosen to 
screen the association at prima facie. No significant association between GPER genotypes 
(CC, CT and TT) in total population (0.647 ± 0.005; 0.642 ± 0.006, 0.651 ± 0.012 respectively; 
p=0.726) and women (0.637 ± 0.006, 0.636 ± 0.007, 0.631 ± 0.014; p=0.944) of group-I and 
in total population ((0.745 ± 0.006, 0.748 ± 0.007, 0.736 ± 0.013; p=0.764) and women 
(0.741 ± 0.008, 0.739 ± 0.009, 0.734 ± 0.015; p=0.944) of group-II were observed- [Table 
15]. 
To deepen our research, we further sorted our data of the common participants 
from the 10 year follow up study. A total of 512 subjects (men= 206; women=306) were 
stratified according to rs11544331 variants of GPER gene and association study were 
performed to see their influence on the progression of cIMT. No association were observed 
neither at baseline (p= 0.250) nor after 10 year follow up study (p=0.877) in total cohort. 
Same were true when analysed for men and women cohort for baseline and in 10 year 
longitudinal study (p= 0.846 vs p=0.112 respectively; p= 0.942 vs 0.863 respectively)- [Table 
16]. 
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Table 15. Representation of intima-media thickness of carotid artery according to rs11544331 
genotypes of GPER gene in PLIC subjects of Group I and II. 
  
GROUP-I (N=1405; Men=575  
; Women = 830) 
  
GROUP-II (n=898; Men=354; 
Women= 544) 
 
 All CC CT TT p All CC CT TT p 
Total 
0.646 ± 
0.003 
0.647 ± 
0.005 
0.642 ± 
0.006 
0.651± 
0.01 
0.320 
0.746 ± 
0.004 
0.745 ± 
0.06 
0.748 ± 
0.007 
0.736 ± 
0.013 
0.764 
Men 
0.65 ± 
0.005 
0.66 ± 
0.008 
0.651 ± 
0.006 
0.678 ± 
0.021 
0.405 
0.755 ± 
0.007 
0.75 ± 
0.009 
0.76 ± 
0.011 
0.74 ± 
0.025 
0.56 
Women 
0.636 ± 
0.004 
0.637 ± 
0.006 
0.636 ± 
0.007 
0.631± 
0.01 
0.944 
0.740 ± 
0.005 
0.741 ± 
0.008 
0.739 ± 
0.009 
0.734 ± 
0.015 
0.94 
 
Note:-  Intima-media thickness was measured in millimetres and Values are indicated in Mean ± SEM, 
and p-value considered significant if less than 0.05. 
 
Table 16.  Prospective studies of PLIC subjects representing the intima-media 
thickness of carotid artery according to rs11544331 genotypes of GPER at baseline and 10 
years follow up. 
  Total (n=512) Men (n=206) Women(n=306) 
 Baseline After 10 yr Baseline After 10 yr Baseline After 10 yr 
All 0.623 ± 0.005 0.739 ± 0.005 0.637 ± 0.009 0.747 ± 0.008 0.614 ± 0.007 0.733 ± 0.007 
CC 0.621 ± 0.007 0.731 ± 0.007 0.632 ± 0.01 0.734 ± 0.01 0.613±  0.009 0.729 ± 0.01 
CT 0.628 ± 0.009 0.750 ± 0.009 0.643 ± 0.015 0.771 ± 0.015 0.616 ± 0.01 0.737 ± 0.01 
TT 0.618 ± 0.02 0.728 ± 0.01 0.634 ± 0.04 0.723 ± 0.03 0.607 ± 0.02 0.731 ± 0.02 
p 0.877 0.250 0.846 0.112 0.942 0.863 
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SECTION [B3]:- IDOL ACTIVITY ON LIPID METABOLISM AND PERIPHERAL ATHEROSCLEROSIS PROGRESSION  
4.22.   IDOL genotype and allelic distribution frequency 
No deviation from the Hardy-Weinberg equilibrium was observed for the rs9370867 
(c.G1025A) SNP. In the PLIC population analyzed (n=1384) the allelic frequencies were 
48.01% and 51.99% for the G and A allele respectively, no significant differences in the 
genotypes distribution between men (n=485) and women (n=899) were observed [Table 
17]. 
Table 17. Genotypic [n(%)] and allelic frequencies (%) of the rs9370867 SNP in the PLIC population. 
  Genotype  Allele 
 n GG GA AA  G A 
PLIC 1384 328(23.7%) 673(48.6%) 383(27.7%)  48.01% 51.99% 
Men 485 127(26.2%) 230(47.4%) 128(26.4%)  49.9% 50.1% 
Women 899 201(22.4%) 443(49.3%) 255(28.4%)  47% 53% 
χ2 2.621 2.552 
P-value 0.454 0.110 
 
4.23. General and clinical characteristics of PLIC subjects according to the 
rs9370867 SNP. 
No major differences were found in the anthropometric and biochemical 
parameters, such as total cholesterol (TC), LDL-C, high density lipoprotein cholesterol (HDL-
C), triglycerides (TG) and glycemia among carriers of the different genotypes. [Table 18]. 
Previous association of the rs9370867 SNP with cholesterol metabolism were observed in a 
Mexican dyslipidemic population, characterized by high levels of TC and TG. For this reason 
we stratified the PLIC population according to TG and TC plasma levels and we repeated the 
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analysis in two sub-groups upper the 75th percentile of TC ( mean value 271.2 ± 23.7 mg/dL) 
and TG ( mean value 191 ± 71,1mg/dL). The results were similar compared to the whole 
population and showed no significant impact of the rs9370867 (c.G1025A) SNP on the lipid 
profile [Table 19 A& B]. 
 
Table 18. Anthropometric and biochemical characteristics according to the rs9370867 SNP in subjects from the 
PLIC population 
 GG AG AA 
P-value GG 
vs AA 
P-value GG 
vs GA 
P-value AA 
vs GA 
Age 65.21 ±  9.97 64.36 ± 1.084 64.90 ± 9.88 0.735 0.342 0.515 
Body mass index (Kg/m2) 26.8 ± 4.6 26.7 ± 4.3 27.0 ± 4.2 0.756 0.739 0.456 
Total cholesterol (mg/dL) 209.9 ± 35.9 206.1 ± 34.6 204.7 ± 34.3 0.089 0.172 0.570 
LDL-cholesterol (mg/dL) 125.2 ± 32.8 123.3 ± 31.9 122.6 ± 31.6 0.356 0.449 0.775 
HDL-cholesterol (mg/dL) 64.60 ± 18 63.08 ± 16.18 62.64 ± 14.8 0.168 0.249 0.701 
Triglycerides (mg/dL) 100.5 ± 42.4 98.91 ± 48.0 97.27 ± 45.6 0.391 0.646 0.634 
Apolipoprotein A-I (mg/dL) 158.2 ± 23.4 156.4 ± 21.0 155.3 ± 20.7 0.133 0.311 0.455 
Apolipoprotein B (mg/dL) 108.7 ± 22.1 105.6 ± 22.2 107.0 ± 22.2 0.389 0.078 0.380 
SBP (mmHg) 128 ± 17 129 ± 18 128 ± 18 0.568 0.352 0.749 
DBP (mmHg) 82.03 ± 9.4 82.37 ± 8.7 82.32 ± 8.8 0.983 0.228 0.195 
Glucose (mg/dL) 95.38 ±15.89 94.97 ± 17.93 92.94±13.72 0.057 0.762 0.091 
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Table 19. Clinical characteristics according to the rs9370867 SNP in subjects from 
the PLIC population included in the upper 75th percentile of total cholesterol (A) and 
triglycerides (B).- Multivariate Analysis. 
19[A] Upper 75th percentile of Total Cholesterol 
 
GG 
(n= 74) 
AG 
(n= 130) 
AA 
(n= 72) 
P-value 
GG vs 
AA 
P-value 
GG vs 
GA 
P-value 
AA vs 
GA 
Age 61.97 ±10.58 63.06 ± 10.08 64.97 ± 10.22 0.293 0.708 0.207 
Body mass index (Kg/m2) 27.2 ± 4.2 25.8 ± 3.9 26.1 ± 3.3 0.198 0.076 0.340 
Total cholesterol (mg/dL) 249.57 ± 21.7 249.76 ± 18.58 248.90 ± 21.54 0.866 0.593 0.850 
LDL-cholesterol (mg/dL) 158.83 ± 25.0 161.87 ± 22.16 160.20 ± 23.01 0.595 0.488 0.340 
HDL-cholesterol (mg/dL) 68.57 ± 19.57 65.08 ± 16.04 65.63 ± 14.18 0.208 0.401 0.078 
Triglycerides (mg/dL) 110.86 ± 47.65 114.02 ± 53.71 115.38 ± 53.99 0.601 0.465 0.357 
Apolipoprotein A-I (mg/dL) 161.41 ± 25.46 159.54 ± 22.59 158.01 ± 18.38 0.101 0.094 0.060 
Apolipoprotein B (mg/dL) 130.88 ± 19.82 132.85 ± 18.16 131.72 ± 21.18 0.525 0.809 0.265 
Glucose (mg/dL) 95.08 ± 12.46 93.64 ± 11.78 91.35 ± 8.88 0.201 0.093 0.941 
Left Ventricular Mass 184.95 ± 64.78 156.48 ± 66.93 165.74 ± 71.88 0.268 0.109 0.677 
cIMT 0.74 ± 0.14 0.75 ± 0.17 0.77 ± 0.15 0.607 0.806 0.424 
SBP 125.0  ± 16.0 132.0  ± 20.0 126.0  ± 14.0 0.076 0.036 0.107 
DBP 78.0 ± 9.0 80.0 ± 12.0 77.0 ± 7.0 0.205 0.154 0.126 
 
(Table 19B) Upper 75th percentile of Triglycerides 
 
 
 
 
 
 
GG 
(n=43) 
AG 
(n = 81) 
AA 
( n= 41) 
P-value 
GG vs AA 
P-value 
GG vs 
GA 
P-value 
AA vs 
GA 
Age 62.42 ± 10.25 64.10 ± 10.55 64.33 ± 8.77 0.288 0.575 0.563 
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Body mass index 
(Kg/m2) 
28.0 ± 5.5 27.1 ± 4.1 28.4 ± 3.9 0.495 0.663 0.233 
Total cholesterol 
(mg/dL) 
220.53 ± 39.86 221.86 ± 35.22 224.95 ± 41.25 0.678 0.476 0.234 
LDL-cholesterol (mg/dL) 134.11 ± 38.80 136.27 ± 34.15 137.33 ± 40.20 0.987 0.332 0.322 
HDL-cholesterol (mg/dL) 52.81 ± 11.16 49.02 ± 11.34 51.07 ± 13.29 0.503 0.525 0.167 
Triglycerides (mg/dL) 168.05 ± 38.67 182.85 ± 55.85 182.76 ± 57.24 0.483 0.161 0.485 
Apolipoprotein A-I 
(mg/dL) 
145.84 ± 19.88 142.77 ± 18.69 141.83 ± 18.12 0.221 0.591 0.434 
Apolipoprotein B 
(mg/dL) 
118.42 ± 25.87 118.16 ± 24.72 119.07 ± 27.01 0.964 0.338 0.297 
Glucose (mg/dL) 96.77 ± 16.90 99.42 ± 26.12 100.17 ± 16.21 0.482 0.651 0.218 
Left Ventricular Mass 190.64 ± 58.76 167.56 ± 60.78 200.33 ± 84.51 0.494 0.295 0.069 
cIMT 0.79 ± 0.18 0.78 ± 0.19 0.76 ± 0.14 0.297 0.433 0.745 
SBP 130.0 ± 17.0 134.0 ± 18.0 129.0 ± 21 0.65 0.193 0.384 
DBP 79.0 ± 70 83.0 ± 10.0 78.0 ± 6.0 0.81 0.008 0.003 
 
4.24. Impact of the rs9370867 SNP for IDOL on carotid atherosclerosis and the 
prevalence of cardiovascular events.  
Although no association between the rs9370867 SNP and LDL-C or other lipid 
variables were observed, this does not exclude the possibility that this functional SNP might 
affects other pathways associated with cardiovascular disease. Therefore to further 
investigate the potential role for the rs9370867 SNP, its association with left ventricular 
mass and intima media thickness of carotid arteries  (Figure 32 A and B) and the incidence 
of coronary heart disease, peripheral artery disease and cardiovascular events (CHD, PAD 
and CVE) was investigated (Figure 33 A to D). The results show that the rs9370867 genotype 
is not associated with any of the parameters investigated. Also when carriers of the A allele 
both in homozygosis and in heterozygosis were compared to carriers of the G allele, no 
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differences in the odd ratio for the incidence of CHD, PAD or CVE were observed. These data 
limit the impact of rs9370867 SNP for IDOL on cardiovascular outcome.  
 
 
Figure 32. Heart left ventricular mass and carotid intima media thickness of the  
common carotid arteries in the PLIC population according to the rs9370867 IDOL  
SNP 
 Panel A shows the mean ± SD for left ventricular mass for GG, AG or AA carriers. Panel B shows the  
mean ± SD of carotid intima media thickness of the common carotid arteries (right and left) for GG,  
G or AA carriers. 
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Figure 33. Incidence of coronary heart disease (CHD), peripheral artery disease (PAD)  
and cardiovascular events (CVE) in the PLIC population according to the rs9370867  
SNP. 
Panels A, B and C shows the incidence of CHD, PAD and CVE for GG, AG or AA carriers of the rs9370867  
IDOL SNP. Panel D reports the OR (Odd Ratio), the 95% Confidence Interval (C.I.) and the P- values for  
CHD, PAD and CVE for carriers of the A allele of the rs9370867 SNP.  
 
 
4.25. LDLR expression and activity according to the rs9370867 SNP. 
The relevance of the rs9370867 IDOL SNP on LDL-R expression was further 
investigated in macrophages generated from peripheral blood mononuclear cells from 
N342 or S342 IDOL carriers. LDL-R expression and the capacity to internalize LDL particle, as 
a functional readout of the LDL-R activity. LDL-R mRNA expression and IDOL mRNA 
expression were similar in N342 and S342 macrophages (Figure 34 A) and more importantly 
the genotype was not associated with differences in LDLR function. N342 and S342 
macrophages showed indeed the same levels of LDL uptake, as assessed by flow cytometry 
after incubation of the cells with fluorescently labelled LDL particle (Figure 34 B and C). 
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Figure 34. mRNA expression of LDL-R and IDOL and LDL uptake in macrophages from 
N342 and S342 macrophages.  
Panel A shows mRNA expression for LDL-receptor and for IDOL in macrophages obtained from N342 
and S342 carriers (n=5 for both genotypes) cultured in complete RPMI medium The results, normalized for the 
expression of an housekeeping gene (18S), data are shown as mean ± SEM. Next flow cytometry was used to 
study the LDL uptake in macrophages obtained from N342 or S342 carriers. To determine the LDL uptake, 
macrophages were incubated with fluorescently labelled LDL (DiO-LDL, 10 µg/mL) for 2 hours at 37°C. Panel B 
shows representative images for flow cytometry in N342 and S342 macrophages, with the gating strategy of 
macrophages (inside panel) and the fluorescence intensity for Dio-LDL while panel C shows the results from 
five N342 and five 342 patients (mean intensity fluorescence is given,  mean ± SEM is shown). 
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In my studies I have intended to understand and characterise the role of three genes 
(known to regulate LDL-R) over lipid metabolism, glucose homeostasis and their role on the 
progression of peripheral atherosclerosis. For that purpose, the study was conducted on 
both mice and human models. In addition, certain functional characterisation of selected 
genetic polymorphism was also conducted in in-vitro studies. 
The major findings of my study is divided into the direct role of PCSK9 protein in 
carotid atherosclerosis progression and glucose metabolism in mice models, while the 
selected genetic variants of three genes (PCSK9-R46L, IDOL-N342S and GPER-P16L) were 
evaluated for their association with anthropometric parameters, lipid phenotypes and 
peripheral atherosclerosis progression in human subjects those were enrolled in our PLIC 
(progression of lesion in intima-media of carotid artery) study.  
5.1 MICE STUDY 
In mice, I have studied the physiological role of PCSK9 protein on LDLR activity and 
glucose homeostasis which was further extended to study our hypothesis of PCSK9 role in 
vascular plaque modulation- derived from our previous findings related to PCSK9 secretion 
by vascular cells[163].  
Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to LDL receptor (LDLR) 
and targets it for lysosomal degradation in the cells. Decreased hepatic clearance of plasma 
LDL-cholesterol is the primary concern of PCSK9 activity. For this reason, we have evaluated 
the effective role of PCSK9 in our studied mice models, the two line of mice carrying PCSK9 
allele (PCSK9 WT) and null allele (PCSK9- KO) were first generated and evaluated for the 
effective role of PCSK9 over LDLR viability. Our results indicate that, mice carrying PCSK9 
allele (WT) causes about 71% reduction in LDLR expression when compared to PCSK9-KO 
mice. This reduction of cholesterol was further seen in reduction in circulating HDL particle, 
since HDL is the prominent cholesterol carrier in mice, PCSK9-KO mice also presented the 
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less HDL particle (about -50%) in lipoprotein fractionation profile (FPLC), might be due to 
high in LDLR expression leading the rapid clearance of ApoE containing lipoproteins. 
The information of PCSK9 role on hypercholesterolemia is well established, although 
the role of PCSK9 on atherosclerosis progression is still under investigation, however, few 
recent studies have correlated plasma PCSK9 levels with carotid atherosclerosis as 
measured by carotid intima-media thickness (cIMT), and was found associated in 
heterozygous (He) FH subjects[79], in chronic chest pain subjects who underwent 
angiography[164], in hypertensive cohort [80], and was also seen associated with PCSK9 
allelic changes like E670G[165].  
These reports prompted us to evaluate the direct role of PCSK9 in peripheral 
atherosclerosis progression. In virtue, we have previously demonstrated that PCSK9 was 
locally produced by vascular smooth muscle cells (VSMCs) and might play a leading role in 
the modulation of atherosclerotic plaque composition[163], for this reason we first aim to 
evaluate the direct role of PCSK9 with atheroma burden. We utilised the advantage of pre-
established perivascular technique, and compared the neo-intimal lesions induced by peri-
adventitial carotid placement of a non-occlusive collar in mice of both genotypes (PCSK9 WT 
and PCSK9-KO). We have observed a remarkable reduction of about 49% in intimal 
thickening in PCSK9KO mice when compared with PCKS9-WT mice (12.344 ± 1.66 vs 23.95 ± 
1.82µm²; p=0.049) [Figure 18], this reduction was further characterised where carotid 
lesions had reduced smooth muscle cells (SMC) content of about 49% in comparison to the 
carotids of PCSK9WT mice (10.7 ± 1.97 vs 21.0 ± 7.56%; p= <0.05)-[Figure 19].,. The 
characterisation of vascular smooth muscle cells (VSMCs) derived from both genotypes 
further revealed the dedifferentiated profiling of VSMCs rapidly occurs in PCSK9-WT mice, 
where PCSK9-KO mice had higher α-actin (VSMCs contractile marker) and lesser caldesmon 
(VSMCs synthetic marker) mRNA levels in comparison to PCSK9-WT mice[Figure 20].,. These 
Vascular cells from PCSK9-KO mice also had reduced doubling time profile of about 47% in 
proliferation and low migration profile than PCSK9WT mice [Figure 21-22]. Therefore we 
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report that PCSK9 deficiency not only maintain the healthy lipid profile but further reduces 
the risk of peripheral atherosclerosis, however we have not seen the similar outcomes when 
evaluated the carotid atherosclerosis progression in human subjects carrying the PCSK9-
loss-of-functioned (p.R46L) gene variants, the results from carotid scanning of R46L subjects 
had the similar progressive profile as of PCSK9 R46R carriers. PCSK9 R46L is a non-
synonymous change and leads the impairment of PCSK9 secretion from hepatocytes. The 
phenotypes of PCSK9 R46L mimics the PCSK9 partial deficient profile at certain extent. 
However, we have seen a dramatic impact of R46L change over glucose and lipid 
metabolism-will be discussed further.  
We further characterize the role of PCSK9 in glucose homeostasis- which was also 
existed with admixed results from several studies, we use the high-fat diet (HFD) as a model 
for impaired glucose tolerance (IGT). All mice of each group (PCSK9 -WT and PCSK9-KO) 
were fed a high fat diet (45% kcal energy by fat) and a normal control SFD-diet (11 % fat). 
Intraperitoneal glucose challenge revealed a modest increase in glucose intolerance in 
PCSK9-KO mice from time 20 min onwards, we further challenged the mice with 
intraperitoneal insulin and checked the glucose absorbance, no difference were observed 
in glucose disposal at different check points upon insulin injection, suggesting that PCSK9-
KO mice might have some defect in pancreatic beta cells. Our data suggest that the absence 
of PCSK9 allele causes the slow metabolic rate leads to glucose intolerance phenotypes 
probably due to pancreatic islet abnormalities, and this was also true in case of humans, 
where PCSK9 R46L carriers also found with high in plasma glucose levels than R46R carriers 
(p<0.004;Table 2). First in mice, the energy intake and weights of mice throughout the 
intervention was similar between the mice group (PCSK9-KO vs WT) of each dietary set (HFD 
vs control). However, the difference was observed in growth curve of glucose absorbance 
measured by glucose tolerance test (GTT), performed at two check points (of week 12th and 
20th). The outcomes of glucose absorbance difference between the twos (PCSK9-KO vs WT) 
of high fat diet groups observed in early intervention phase (week 12th post-inception), 
which further emerged as a strong phenotype during the late intervention phase (week 20th 
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post-inception). We have observed the mild phenotypes of glucose intolerance was existed 
after time 60min post glucose challenge in early week 12 of intervention phase while the 
phenotypes of glucose intolerance was more stronger when characterised in late 
intervention phase of week 20th, where low glucose disposal was existed right from the time 
20 min and it was remained higher uptil 120min [Figure 25]. The support of our supposition 
of pancreatic islet cell abnormalities arose from the intraperitoneal insulin challenge test 
and hepatic gene expression profiling, where intraperitoneal challenge of insulin in twos 
(PCSK9KO and WT) of HFD- groups did not have significant difference in glucose disposal 
rate [Figure 26], neither had any difference in hepatic insulin receptor gene expressions- 
determined by internally controlled reverse transcriptase polymerase chain reaction (RT-
PCR), both insulin receptors IRS-1 and IRS-2 mRNA  in PCSK9 KO and WT had similar pattern 
of expressions in HFD-diet group [Figure 27], suggesting that the slow metabolic rate or slow 
glucose disposal rate in PCSK9KO mice is might be due to the impaired secretion of insulin 
from pancreatic beta cells and thus causing hypoinsulinemic and hyperglycemic profile. Our 
this findings also goes in line to the research conducted by Mbikay et al [71].  
Similarly, we have observed the same phenotypes when studied in humans, our 
study on common PCSK9 LOF variant (p.R46L), also displayed the similar results in humans. 
This non-synonymous change (p.R46L) on PCSK9 gene causes defect in PCSK9 autocatalytic 
activity and hence impairs its secretion from hepatocytes, leads in causing low in plasma 
PCSK9 volume. Therefore our study on PCSK9 association with glucose homeostasis on 
humans subjects also draw the same results as seen in mice, the low levels of plasma PCSK9 
was associated with subjects carrying R46L allele and presented about 7% higher in plasma 
glucose levels than subjects carrying R46R allele [Table 2]. Therefore our data from both 
mice and human suggest that PCSK9 deficiency causes impaired glucose tolerance due to 
pancreatic islet abnormalities. Although, our results are contradictory to the observatory 
data accrued from clinical trials of PCSK9 monoclonal antibodies, however require long term 
follow ups. 
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5.2  IN HUMANS 
In humans, my study was begin with the thirst to observe the PCSK9 related 
phenotypes as seen in mice study. For that reason, we have opted to dissect the role of 
PCSK9 polymorphic activity which mimics the PCSK9 partial deficiency in humans. We 
choose PCSK9 rs11591147 (p.R46L) variants for our study. PCSK9 p.R46L is known as a 
common variant in Caucasian subjects and represents minimal circulating plasma PCSK9 
levels. Similarly, the simultaneous selected polymorphisms of IDOL gene (rs9370867; 
p.N342S) and GPER gene (rs11544331; p.P16L) were also studied those were identified in a 
genome-wide association study (GWAS) based studies and found associated with lipid 
levels. The general information about studied genes mentioned in Discussion table 1. 
The initial screening of studied variants was their penetration and the effect size in 
our population [Discussion table 2], the frequencies of all the loci (PCSK9 and GPER) were 
similarly matched as found in other referred population except the causal allele of IDOL 
gene [Discussion table 3]. The studied allelic frequencies of PCSK9 (rs11591147; p.R46L)) 
and IDOL (rs9370867; p.N342) in different population can be seen in Discussion table 4 
The spectrum of studied genetic variants of PCSK9 (p.R46L), GPER(p.P16L) and  IDOL 
(p.N342S) gene with clinical variables in our studied cohort was not too strong as seen in 
various other population based studies, however this disparity might be due to the various 
dependent variables like demographic change, ethnicity, life styles etc.  The magnitude of 
effect of homozygous mutated loci of each studied gene when evaluated for their 
association with LDL-c and total cholesterol levels against their respective homozygous wild 
type allele was maximally associated with increase of 3.52mg/dL and 5.23mg/dL 
respectively of mean levels in case of GPER p.P16L polymorphisms while it was only 
2.6mg/dL and 5.2mg/dL respectively in case of IDOL p.N342S polymorphism. However, the 
studied polymorphism of PCSK9 gene (p.R46L) is a loss-of-functioned (LOF) variants and 
presents a better lipid profile, in our case the carriers of 46L (n=42) had about 10.2 mg/dL 
and 9.75 mg/dL reduced levels of LDL-c and total cholesterol respectively than subjects 
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carrying homozygous 46R allele [Discussion table 5]. In addition, as expected carriers of 46L 
had about 7.2 mg/dL of increased mean levels of glucose levels (p=<0.004), and 2.43mg/dL 
in case of GPER 16L carrier but could not reach to the statistical significance (p=0.06), while 
it was reverse in case of IDOL where supposedly homozygous mutated allele (342S) carriers 
had increased glucose levels by 2.44mg/dL than 342N carriers (p=0.057).  Other variables 
like BMI, triglycerides, HDLc, ApoA1, ApoB, SBP, DBP and cIMT did not reach to the statistical 
significance in case of IDOL and GPER gene variants. However, subjects carrying PCSK9 p.46L 
allele also had reduced HDL (p=0.022) as expected but increased triglycerides (p=0.004) 
levels [Discussion table 6]. 
Our study suggest that, except PCSK9 p.R46L variants, not other studied loci had 
profound impact on lipid phenotypes neither on anthropometric parameters and nor on 
cIMT progression [Discussion table 7]. PCSK9 allele R46L was associated with significantly 
beneficial profile with a range of effects on plasma levels of lipoproteins (esp. LDL-C). 
However, we observed that PCSK9 deficiency have both beneficial and harmful outcomes 
(as observed in case of glucose in mice and human too). 
Our next examination was on the levels of plasma PCSK9 protein. Here we studied 
the effects of our selected gene polymorphisms of PCSK9 (rs1191147; p.R46L), GPER 
(rs11544331; p.P16L) and IDOL (rs9370867; p.N342S) on plasm PCSK9 levels. This study not 
only unravel the effects of PCSK9 R46L variants on plasma PCSK9 but also attributed further 
in our knowledge about the ecstatic effect of other studied genes like GPER and IDOL 
[Discussion table 8].  Since, hypolipidemics drugs (like statins) have confounding effect over 
PCSK9 expression [Figure 27], thus we have only selected subjects those were free of 
hypolipidemics drugs. GPER studied variant (rs11544331; p.P16L) but not IDOL gene variants 
(rs9370867; p.N342S) had profound influence on the plasma PCSK9 levels (p=0.045), 
however was found sex specific (p=0.043). Women carriers of GPER mutated allele (16L 
carrier) had about 112ng/mL of elevated plasma PCKS9 levels than women carriers of 
homozygous wild type allele (p=0.015). The difference in plasma PCSK9 were further 
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statistical relevant when compared with men of similar 16L carrier (p=0.029) [Discussion 
table 9]. The reason behind the regulation of PCSK9 expression via GPER activity is not 
known, however, the regulatory action of estrogen on PCSK9 levels might be explained by 
GPER activity. In one study, overexpression of IDOL gene also had a profound effect on 
PCSK9 protein expression [166], and GWAS based identified polymorphism rs9370867 
(p.N342S) on IDOL gene also had increase in lipid profile, might also indicate the co-
ordinating activity with PCSK9 protein. However, in our study we found neutral activity of 
IDOL polymorphism (rs9370867; p.N342S) not only on lipid phenotypes, cIMT but also when 
studied their effect on plasma PCSK9 levels (p=0.092).  
However, when analysed for PCSK9 R46L variants, the dramatic changes in plasma 
PCSK9 variants (R46L) levels were seen in total population and that was irrespective of 
gender we found a drop of about 157.36ng/ml of PCSK9 in subjects carrying 46L (mutated 
allele) when compared with 46R carriers(p<0.001), and a significant drop in both men (-40%; 
p=0.04) and women (-57.38%; p=0.001) were found [Discussion table 8 & Discussion table 
9]. 
Our observation suggest that not only the variants of PCSK9 gene but other gene 
variants also influences plasma PCSK9 levels. 
We further investigated the role of plasma PCSK9 levels irrespective to the effect of 
gene variants. The distribution of plasma PCSK9 levels in our studied population was not 
normally distributed, a wide range of PCSK9 levels were found (8ng/ml- 1432ng/ml) in the 
population, this might be due to the high in number of women and aged people in our 
studied population. The mean level of plasma PCSK9 in total population was 285.3 ng/ml, 
while it was higher in women than men cohort (296.35 vs 267.84 ng/ml; p= 0.008). The 
levels in women was further found maximum in post-menopausal phase than pre-
menopausal phase (p=0.007)- [Figure 28]. Subjects with lipid lowering drugs also had higher 
trend of plasma PCSK9 levels than subjects without lipid lowering drugs (p<0.001)[Figure 
29]. When evaluated further, plasma PCSK9 levels were found associated with various lipid 
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variables in both univariate analysis and after adjustment for age and gender in a 
multivariate regression analysis, including Total cholesterol (p<0.001, β=0.196), LDL 
(p=0.002, β=0.094), HDL (p<0.001, β=0.124), triglycerides (p<0.001; β=0.114), however all 
these association were found modestly stronger in men than women cohort [Table 6]. 
Although there was no association of plasma PCSK9 with blood pressure and glucose levels 
was appeared in a univariate and multivariate analysis, but the associations with lipid 
parameters prompted us to evaluate the role of PCSK9 in a metabolic syndrome (MetS) 
phenotype, As expected, a group of MetS subjects had about 8% (22ng/ml) higher plasma 
PCSK9 levels than subjects without MetS phenotypes (p=0.016), this was further found 
related with men cohort, when performed genderwise analysis. Men cohort of MetS but 
not women cohort had a significant elevation of plasma PCSK9 levels than men of non-MetS 
group (p=0.04) [Table 7].  
As stated before there was no association of IDOL gene and GPER gene 
polymorphisms on the lipid levels were appeared in our population based study. However, 
a strong association of IDOL polymorphism with lipid levels was described in GWAS 
study[160] and in Mexican population based study[9], which prompted us to characterise 
the functionality of IDOL SNP (rs9370867; p.N342S) at in-vitro level too, the selected 
subjects of the IDOL p.N342S genotypes (AA and GG) were re-called and analysed further 
for LDLR expression and variability in LDL uptake, as expected, no variation in LDLR 
expression and LDL uptake were observed among the IDOL genotypes.  
Our observation suggest that among the studied genetic variants of three genes 
(PCSK9, GPER, and IDOL)  only PCSK9 variants (R46L) have profound effect on lipids and 
glucose levels,  while no association with lipid and glucose was found when studied for  GPER 
(p.P16L) and IDOL (p.N342S) in Italian population. Neither of three studied loci (PCSK9, GPER 
and IDOL) have any influence on intima-media thickness of carotid artery (cIMT). Further, 
PCSK9 p.R46L and GPER p.P16L variants influences plasma PCSK9 levels. These plasma 
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PCSK9 levels had high impact on lipid variability and found increased in subjects with 
metabolic syndrome phenotypes. 
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In My study- among the three studied genes, PCSK9 role on glucose homeostasis is 
clearly demonstrated in both mice and human subjects, however its role on carotid 
atherosclerosis progression still require more study. Higher plasma PCSK9 levels also 
marked huge impact on lipoprotein levels and increases in subjects with metabolic 
syndrome (MetS) phenotypes, all these associations were more strongly appeared in case 
of men. While GPER and IDOL studied polymorphisms have no influence on lipid 
metabolism, glucose levels and peripheral atherosclerosis progression in Italian general 
population. Although, we observed that GPER variants are associated with sex-specific 
elevation of plasma PCSK9 levels and require further investigation for the underlying 
molecular mechanism. 
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 [A] From Mice study 
1. Proprotein convertase subtilisin/kexin type 9 (PCSK9) protein induces hepatic 
LDLR degradation and hence increases plasma cholesterol level. 
2. Upon perivascular manipulation- the presence of PCSK9 increases the risk of 
neo-intimal hyperplasia, probably due to enhanced dedifferentiating 
phenotypes of underlying vascular smooth muscle cells. 
3. PCSK9 deficiency however found linked to glucose intolerance. 
 
 
[B]   From Human study 
(i) Findings from Proprotein convertase subtilisin/kexin type 9 (PCSK9) study 
1. The role of loss-of-functioned (LOF) variant of PCSK9 rs11591147 (p.R46L) 
presents favourable lipid phenotype profile. 
2. Similar to the mice, PCSK9 p.R46L causes increase in blood glucose levels. 
3. PCSK9 p.R46L carriers also presents low plasma PCSK9 levels. 
4. This partial deficient phenotype of PCSK9 did not present significant impact on 
reduction of intima-media thickness of carotid artery (cIMT)-as shown in mice 
study with PCSK9 deficient phenotype. 
5. Plasma PCSK9 levels are highly varied in Italian general population. 
6. Plasma PCSK9 levels are age and sex dependent- women carries higher plasma 
PCSK9 levels than their age-matched men, and PCSK9 levels further goes 
maximum upon menopause. 
7. Hypolipidemic drugs (like Statins) increases plasma PCSK9 levels. 
8. Plasma PCSK9 levels found associated with various lipoproteins, including LDL, 
HDL, Triglycerides, ApoAI, and ApoB. 
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9. High Plasma PCSK9 levels does not promote carotid atherosclerosis progression 
neither glucose intolerance, while low levels of PCSK9 affects glucose 
metabolism.  
10. Men with high plasma PCSK9 levels present modest associations with clinical 
variables while women are generally protected. 
11. Plasma PCSK9 levels increases in men with metabolic syndrome phenotypes. 
 
(ii) Findings from G-protein coupled estrogen receptor (GPER) study 
 
1 GPER rs11544331 (p.P16L) variants does not alter lipid levels and neither   
       Influences intima media thickness of carotid artery (cIMT) - in Italian general     
       population. 
2  Neither sex-specific influence of GPER p.16L on lipid variables were found as 
seen in other referred studies. 
3 GPER p.P16L variants however increases plasma PCSK9 levels in women. 
 
 
(iii) Findings from Inducible degrader of LDL-R (IDOL) study 
 
1. IDOL rs9370867 (p.N342S) variants does not alter glucose and lipid variable in 
Italian general population. 
2. Neither IDOL p.N342S variants influences plasma PCSK9 levels nor intima-
media thickness of carotid artery in Italian general population. 
3. The in-vitro functional characterization of IDOL p.N342S variants also did not 
present the functional difference among the genotypes for LDLR expression 
and LDL uptake ability. 
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Discussion table 1. GWAS identified and PLIC studied loci-associated with Lipid phenotypes and CHD 
 
Gene Chromosome 
Chromo-
some 
position 
Contig 
position 
rs number Location 
Nucleotide 
change 
Amino 
acid 
change 
Unicluster 
ID 
Population 
studied 
Reference 
PCSK9 1p32 55039974 54453986 rs11591147 Exon c.5428. G>T p.R46L 18844 Whites, PLIC [167] 
GPER 7p22.3 1091775 1081775 rs115444331 Exon c.47. C>T p.P16L 552573 Ontario, PLIC [150] 
IDOL/MYLIP 6p23 16145325 16085325 rs9370867 Exon c.1025. A>G p.N342S 484738 
Mexican, 
Brazilian, 
PLIC 
[9], [10] 
  
Discussion table 2. Genotype and allelic Frequency of studied loci in PLIC cohort 
  R46L (n=1919); G>T P16L (n=1405); C>T 
N342S (n=1384); A>G 
Frequencies Genotype (n; %) Allelic Genotype (n; %) Allelic Genotype Allelic 
Homozygous (Major 
allele) 
1877; 97.81% 98.90% 674; 47.97% 69.68% 383; 27.7% 51.99% 
Heterozygous 42; 2.19% - 610; 43.42% - 673; 48.6% - 
Homozygous (Minor 
allele) 
NA 1.10% 121; 8.61% 30.32% 328; 23,7% 48.01% 
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Discussion table 3. Comparative genotype and allelic frequency of studied loci in different population. 
 PCSK9 rs11591147 (p.R46L) GPER rs11544331 (p.P16L) IDOL rs9370867 (p.N342S) 
 PLIC (Genotype %) 
Ref study 
(Genotype %) 
[Reference] 
PLIC (Genotype %) 
Ref study (Genotype 
%) [Reference] 
PLIC 
(Genotype%/allelic%
) 
Ref study (allelic 
frequency%) 
[Reference] 
Homozygous (wild 
allele) 
97.81% 96.80% [5] 47.97% 56.34% [150]  27.70%/ 51.99% 25% [9]; 35.72 [10] 
Homozygous 
mutated allele 
2.19% (in 
heterozygous form) 
3.20% (in 
heterozygous 
form) [5] 
8.61% 6.78% [150] 23.70%; 48.01% 75% [9], 64.28 [10] 
 
Discussion table 4. Common allele frequencies of PCSK9 R46L and IDOL N342S polymorphisms in different population 
POPULATION STUDIED FOR PCSK9 (p.R46L; c.5428. G>T; rs11591147) 
 LWK YRI CHD ASW TSI CHB CEU JPT MEX BRAZ PLIC 
G 0.991 1 0.995 0.991 0.985 0.993 0.991 0.991 0.966 - 0.989 
T 0.009 0 0.005 0.009 0.015 0.007 0.009 0.009 0.034 - 0.011 
POPULATION STUDIED FOR IDOL (p.N342S; c.1025. A>G;  rs9370867) 
A 0.032 0.021 0.079 0.105 0.49 0.052 0.514 0.013 0.259 0.357 0.519 
G 0.968 0.979 0.921 0.895 0.51 0.948 0.486 0.987 0.741 0.643 0.481 
ASW- African ancestry in Southwest USA; CEU- Utah residents with Northern and Western European ancestry from the CEPH collection 
CHB- Han Chinese in Beijing, China; CHD- Chinese in Metropolitan Denver, Colorado; GIH- Gujarati Indians in Houston, Texas, JPT- Japanese in Tokyo, Japan; LWK-  
Luhya in Webuye, Kenya, MXL- Mexican ancestry in Los Angeles, California; MKK- Maasai in Kinyawa, Kenya; TSI- Toscani in Italia; YRI- Yoruba in Ibadan, Nigeria, 
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Discussion table 5. Magnitude of effect of the studied Loci (gene variations) reproducibly associated with plasma Lipoprotein 
levels in PLIC subjects 
Effect, 
Sequence 
variation 
and 
Genotype 
No. of 
individuals 
Mean ± 
SEM 
LDLc 
(mg/dL) 
Difference 
in mean 
LDLc 
(mg/dL) 
Mean ± 
SEM 
TC (mg/dL) 
Difference 
in mean TC 
(mg/dL) 
Mean ± SEM 
Tg (mg/dL) 
Difference 
in mean Tg 
(mg/dL) 
Mean ± SEM 
Glucose 
(mg/dL) 
Difference in 
mean 
Glucose 
(mg/dL) 
PCSK9[R46L]; G>T   
GG 1877 
144.58 ± 
0.83 
10.2 
221.85 ± 
0.90 
9.75 
108.61 ± 
1.44 
28.56 
92.83 ± 0.36 
7.2 
GT 42 
134.42 ± 
6.35 
212.10 ± 
6.62 
137.17 ± 
14.0  
100.0 ± 4.18 
P value  0.075  0.113  0.004  0.004  
IDOL[N342S]; A>G;   
AA 383 122.6 ± 31.6 
2.6 
204.7 ± 34.3 
5.2 
97.27 ± 45.6 
3.23 
92.94 
2.44 
GG 328 125.2 ± 32.8 209.9 ± 35.9 100.5 ± 42.4 95.38 
P value  0.356  0.089  0.391  0.057  
GPER [P16L]; C>T   
CC 674 
144.66 ± 
1.37 
3.52 
220.15 ± 
1.48 
5.23 
108.01 ± 2.3 
5.11 
90.08 
2.43 
TT 121 
148.18 ± 
3.11 
225.38 ± 3.2 113.12 ± 6.3 92.51 
P value  0.608  0.271  0.716  0.06  
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Discussion table 6. General and clinical characteristics of PLIC subjects according to loci studied (PCSK9, IDOL and GPER genes.) 
  AGE BMI TC LDLc HDLc Tg ApoA1 ApoB SBP DBP GLUCOSE 
R46L 
RR (GG) 54.77 ± 0.26 
26.48 ± 
0.09 
221.85 ± 
0.90 
144.62 ± 
0.83 
55.52 ± 
0.33 
108.60 ± 
1.44 
149.35 
±0.61 
113.61 
±0.60 
131.40 ± 
0.40 
81.65 ± 
0.22 
92.83 ± 0.362 
RL (GT) 54.17 ± 1.69 
28.14 ± 
0.61 
212.10 ± 
6.62 
134.42 ± 
6.35 
50.24 ± 
1.96 
137.17 ± 
14.0 
139.88 ± 
3.84 
108.95 ± 
4.18 
134.39 ± 
2.50 
83.54 ± 
1.37 
100.0 ± 4.18 
P-VALUE 0.75 0.011 0.113 0.075 0.022 0.004 0.024 0.262 0.275 0.32 0.004 
N342S 
            
NN (AA) 64.90 ± 9.8 27.0 ± 4.2 
204.7 ± 
34.3 
122.6 ± 
31.6 
62.64 ± 
14.8 
97.27 ± 
45.6 
155.3 ± 
20.7 
107.0 ± 
22.2 
128 ± 
18.0 
82.32 ± 
8.8 
92.94 ± 13.72 
NS (AG) 64.36 ± 1.08 26.7± 4.3 
206.1 ± 
34.6 
123.3 ± 
31.9 
63.08 ± 
16.18 
98.91 ± 
48.0 
156.4 ± 
21.0 
105.6 ± 
22.2 
129 ± 
18.0 
82.37 ± 
8.70 
94.97 ± 17.93 
SS (GG) 65.21 ± 9.97 26.8 ± 4.6 
209.9 ± 
35.9 
125.2 ± 
32.8 
64.60 ± 
18 
100.5 ± 
42.4 
158.2 ± 
23.4 
108.7 ± 
22.1 
128 ± 17 
82.03 ± 
9.4 
95.38 ± 15.89 
P-VALUE 0.735 0.756 0.089 0.356 0.168 0.391 0.133 0.389 0.568 0.983 0.057 
P16L 
            
PP (CC) 54.81 ± 0.43 
26.69 ± 
0.17 
220.15 ± 
1.48 
144.66 ± 
1.37 
53.88 ± 
0.54 
108.01 ± 
2.3 
145.78 ± 
0.99 
112.97 ± 
0.97 
132.79 ± 
0.64 
83.09 ± 
0.33 
90.08 ± 0.49 
PL (CT) 54.96 ± 0.45 
26.37 ± 
0.17 
222.66 ± 
1.55 
145.29 ± 
1.46 
55.69 ± 
0.59 
108.33 ± 
2.6 
148.24 ± 
1.0 
112.83 ± 
1.0 
132.96 ± 
0.68 
82.65 ± 
0.37 
92.06 ± 0.79 
LL (TT) 55.10 ± 0.99 
26.82 ± 
0.33 
225.38 ± 
3.2 
148.18 ± 
3.11 
54.57 ± 
1.34 
113.12 ± 
6.3 
147.04 ± 
2.5 
116.25 ± 
2.22 
133.64 ± 
1.7 
83.88 ± 
0.83 
92.51 ± 1.3 
P-VALUE 0.952 0.326 0.271 0.608 0.079 0.716 0.235 0.389 0.878 0.345 0.06 
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Discussion table 7. Comparative of loci effect size in cIMT progression and prospective genetic study 
Gene SNP Baseline (cIMT) 10 yr after (cIMT) 
  (mm) (mm) 
PCSK9 
R46R 0.652 ± 0.003 0.78 ± 0.005 
R46L 0.661 ± 0.017 0.76 ± 0.23 
P-value 0.142 0.116 
IDOL 
N342N 0.639 ± 0.006 0.760 ± 0.07 
S342S 0.634 ± 0.006 0.768 ± 0.005 
p-value 0.205 0.066 
GPER 
P16P 0.64 ± 0.005 0.781 ± 0.007 
L16L 0.65 ± 0.01 0.785 ± 0.171 
p-value 0.726 0.970 
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 Discussion table 8.  Plasma PCSK9 distribution according to studied loci in PLIC subjects (free of hypolipidemics) 
Serial Frequencies PCSK9 - R46L (n=1919); G>T GPER- P16L (n=898); C>T IDOL- N342S (n=1384); A>G 
A Homozygous (Major allele) 294.33 ng/mL 277.49 ± 8.71 ng/mL 266.92 
B Heterozygous 136.97 ng/mL 303.52 ±10.22 ng/mL 301.77 
C Homozygous (Minor allele) - 324.34 ± 20.95 ng/mL 273.15 
 Difference in mean plasma PCSK9 
levels (ng/ml) 
-157.36 [A - B] +46.85 [A - C] +6.23 [A – C] 
 P-value <0.001 0.045 0.53 
Discussion table 9. Plasma PCSK9 distribution in men and women according to studied loci. 
 PCSK9 - R46L (n=1919)  GPER- P16L (n=898); C>T  
Frequencies Men Women p-value Men Women p-value 
Homozygous (Major allele) 276.90 ± 10.91 312.00 ± 10.12 0.32 258.42 ± 8.71 ng/mL 291.25  ± 0.15 
Heterozygous 163.57 ± 41.53 132.98 ± 33.68 0.067 287.39 ±14.99 ng/mL 
313.27  ± 
13.65 
0.23 
Homozygous (Minor allele) NA NA 
 
254.09 ± 35.12 ng/mL 
366.92  ± 
24.13 
0.029 
P-value 0.04 0.001 0.298 0.043 
 % of PCSK9 change with mutated 
allele 
-40% -57.38% -1.67% +24.15% 
 Note:- values are in Mean ±SEM ; and IDOL gene values are not included as there was no significant association.   
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ABI- Ankle-brachial index 
ADH- Autosomal dominant hypercholesterolemia 
ApoAI- Apolipoprotein AI 
ApoB- Apolipoprotein-B 
ApoE- Apolipoprotein-E 
ApoER2- Apolipoprotein-E receptor 2 
ATP-III- National Cholesterol Education Program’s Adult Treatment Panel III report 
CAD- Coronary artery disease 
CAIP- Carotid  artery injury model 
CHD- Coronary heart disease 
cIMT- intima-media thickness of carotid artery 
CVD- Cardiovascular diseases 
CVE-Cardiovascular events 
DBP- Diastolic blood pressure 
DIO- Diet induced obesity 
ERα- Estrogen receptor-α 
ERβ- Estrogen receptor-β 
FBS- Fetal bovine serum 
FH- Familial hypercholesterolemia 
FPLC- Fast performance liquid chromatography 
GOF- Gain of function 
GTT- Glucose tolerance test 
GPCR- G-protein coupled receptors 
GPER- G-protein coupled estrogen receptor 
HDL- High density lipoprotein 
IDOL- Inducible degrader of LDL-receptor 
ITT- Insulin glucose test 
LDL- Low density lipoprotein 
LDLR- Low density lipoprotein receptor 
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LOF- Loss of function 
LRP-  Low density lipoprotein receptor-related protein 1 
MetS- Metabolic syndrome 
PAD- Peripheral artery disease 
PBMC- Peripheral blood mononuclear cells 
PBS- Phosphate buffer saline 
PCR- Polymerace chain reaction 
PCSK9- Proprotein convertase subtilisin/kexin type 9 
PLIC- Progression of lesion in intima-media of carotid artery 
RT-PCR- Real time polymerase chain reaction 
SBP- Systolic blood pressure 
SFD- Standard fat diet 
TC- total cholesterol 
TG- Triglycerides 
VLDL- Very low density lipoprotein 
VLDLR- very low density lipoprotein receptor 
VSMCs- Vascular smooth muscle cells 
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